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Abstract

This honours project is based on the advancement of in situ hybridisation to
metaphase chromosome spreads. The technique was carried out using cosmid probes
which are specific for microdeleted regions on chromosome 22q 11 associated with

Di George syndrome (DGS) and related disorders. Disorders similar to DGS include
partial Di George syndrome, III-IV pha_ryngeal pouch syndrome, velucardiofacial
syndrome (VCFS), conotruncal facial anomaly and the CHARGE association.
Recently the group of disorders with this microdeletion and comparable symptoms
has been summarised by the acronym CATCh 22.

Large deletions, translocations, monosomies, and trisomies of chromosome·!i are
apparent under the light microscope, when prepared as metaphase chromosome
spreads for karyotyping. Subtle microdeletions, however, are seldom detected by
this method, even when high resolution banding techniques are undertaken. A more
suitable technique for the detection of such microdeletions is in situ hybridisation. In

situ hybridisation (ISH) has successful!y been employed to identifY chromosomes, to
detect chromosomal abnormalities, and to determine chromosomal locations of
specific gene sequences.

i

The aim of the present study is to apply in situ

hybridisation to the detection of suspected microdeletions of chromosome 22qll.
Fluorescent in situ hybridisation (FISH) and other forms of non-isotopic in situ
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hybridisation (NISH) were carried out with cosmid probes specif..c for chromosome
region 22qll, on peripheral blood samples of patients displaying DGS-like

symptoms and controls. Patients suspected of having

n:

George syndrome were

surveyed by Dr. S. Worthington at Princess Margaret Hospital for Children (Western
Australia) as part of a clinical study into familial congenital heart disease (CHD).
All patients tested have CHD, and display some DGS-like symptoms.

The

advancement of the FISH technique will assist clinicians in the identification of
patients with the CATCH 22 sequence, and will further serve to demonstrate the
ability of a cosmi.d probe to detect a microdeletion associated with a clinical
disorder. The effectiveness of the method will also be compared to results obtained
by routine cytogenetic analysis. The study shows that although in situ hybridisation

is technically difficult to establish, it holds great promise as a sensitive and specific
diagnostic test and research tool.
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Anti-digoxigenin fluorescein
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CATCH22

The acronym which represents the clinical and genetic features
ofDi George syndrome (i.e., cardiac, abnormal facies, thymic
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Polymerase chain reaction
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Princess Margaret Hospital (WA)
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1.1 Introduction
Di George syndrome (DGS) is a developmental field defect of the third and fourth
brachial arches. It was first described by Angelo Di George (1968), and since that

time numerous clinical, cytogenetic and molecular studies have been undertaken to

·'<

identifY the spectrum of associated defects (Greenberg eta/., 1988a). The clinical

features, which are diverse and vary in severity, include congenital heart disease
(CHD) such as tetralogy of Fallot, interrupted aortic arch, ventricular septal defects

and hypocalcaemia, facial abnormalities and a poor immune system due to the
absence of the thymus. Most patients have evidence of CHD but some may present
only with hypocalcaemic seizures (Conley eta/., 1979). The first recorded familial

cases of DGS were associated with an unbalanced chromosome 20:22 translocation,
which resulted in monosomy 22qll (De Ia Chapelle eta/., 1981). The ability to

detect monosomy 22q II is questionable with routine cytogenetic analysis (Desmaze
et a/., 1993a). The microdeletion which is thought to be responsible for DGS,

however, can be more readily detected by non-isotopic in situ hybridisation (NISH),

.l
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'
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particularly fluorescent in situ hybridisation (FISH) (Carey eta/., 1992). In FISH the

cosmid probe DNA is hybridised to its complementary sequence of chromosomal
DNA, on the particular chromosome where that sequence is found. The cosmid
probe which is used to detect the deletion associated with DGS corresponds to a
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region on chromosome 22q 1L

In FISH the probe DNA is labelled with a

fluorochrome to facilitate detection, and the chromosomes are visualised with an
appropriate counterstain. If fluorescein, a yellow-green fluorochrome, is used to
label the probe then propidium iodide is· applied as the counterstain. The resultant
red-stained metaphase chromosomes are then viewed under fluorescent microscopy,
the hybridisation signal which highlights the chromosome-probe hybrid fluoresces as
a bright yellow signal. In situ hybridisation has been used to detect the presence of
many clinical disorders which localise to specific chromosome regions.
·'i-_,

This

detection method plays an important role in a variety of research areas, including
cytogenetics, tumour biology, gene amplification, gene mapping and also in prenatal
diagnosis (Trask, 1991 ).

1.2. The hjstocy ofDi George syndrome
DOS is named after Angelo Di George, an American clinician, who commenced
research into congenital absence of the thymus in 1963 (Di George, 1968).
However, he probably was not the first person to note the disorder. A journal article
from as early as 1829 by H. Harrington described symptoms similar, if not identical,
to those associated with DGS (Greenberg, 1993). Absence of thymic tissue is also
often associated with loss of the parathyroid glands, or their ectopic placement, and
has resulted in DGS-like symptoms (Lobdell, 1959).

The major presenting

symptoms which allow a provisional diagnosis of the disorder are CHD (De Ia
Chapelle eta/., 1981) and malformations of the palr'1. In DOS patients these are

•·

4

accompanied by a grossly depressed Cell mediated immunity caused by the absence
of the thymus (Greenberg, 1993). During infancy hypocalcaemic seizures are caused

by absence of parathyroids.

1.3. CHnica1 features ofDi George Syndrome
Di George syndrome (DGS) consists of varying combinations and degrees of
hypoparathyroidism, thymic hypoplasia with T-lymphocyte deficiency, congenital
heart disease (CHD), and dysmorphic facies (Winter et al., 1984). Although the

symptoms vary in severity, almost all cases result f

~.

a detectable deletion within

chromosome 22qll (Wilson, D. eta/., 1993b). The array of clinical symptoms
which make up DGS has been summarised by the acronym 'CATCH 22 syndrome'.

This acronym represents the clinical features (Cardiac, Abnonnal facies, Thymic
hypoplasia, Cleft palate, and Hypocalcaemia) and chromosome 22 (Wilson, D. eta/.,
1993b).

CATCH 22 also suggests the complexity which exists with regard to

definition of the clinical features, and understanding the genetic ramifications of a
deletion from a specific area on a particular chromosome (Hall, 1993).

DGS does not, as its title would suggest, have a set of symptoms which are common
to all patients. For this reason DGS and other similar syndromes have been classed
as 'contiguous gene syndromes' (Schrnickel, 1986).

Owing to these varying

symptoms, it has been said of DGS that it probably is not a distinct syndrome of

____ .. ,.,.,,.-cr··,--,--,""7".,~~-.,..~""'"' "'"'"·""'}r~tw-~~- 6,"'!-"'•-, ':"c""'·: _, ';_.:_e_w_s;_t±:A: _. ·:Af-'_'f-'~k!;;t;~?&ij?{¥¥!} :_~,)lB.;~'- .p;q Jl_ .- ·i?WJ~_qgz_q,_,
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single gene origin but rather an anomaly caused by a heterogeneous developmental
field defect (Stevens eta/., 1990).

Due to the variance of symptoms and their possible causes the disease has been given
several names. The disorder associated with microdeletion 22ql I has not only been
known as DGS, but also as lll-lV pharyngeal pouch syndrome and partial Di George
syndrome (Lischner eta/., 1972). Reported cases of partial DGS include apparently
balanced and unbalanced translocations.

A balanced translocation t(2;22)

(ql4.l;qll.l) was observed in a girl with some, but not all, of the features ofDGS.

The same translocation was present in the girl's mother and maternal aunt. The latter
female had her fourth pregnancy aborted due to cardiac and other malformations
which were detected by ultrasound. The karyotypes of individuals in the family

show that this particular translocation can be associated with partial DGS, however

'
~

the fetus which was aborted had a much more severe (complete) form of DGS
-i
'

(Augusseau eta/., 1986).

1.4. DQS as a conti~:uous gene

,'

syndrom~

The heterogeneity of symptoms within families is often associated with contiguous
gene syndromes, which can be grouped into those with detectable chromosomal
detects and those without any identifiable aberration at a cytogenetic level (Emanuel,
1988). One of the forms ofDGS which has been shown to have a translocation at the

.j

cytogenetic level is partial DGS, a disorder that has been noted in many families.
Greenberg et a/., (1984) reported a family in which both siblings had DGS
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phenotype. This phenotype was associated with an unbalanced 4;22 translocation in
the younger child, which resulted in partial monosomy of chromosome 22qll. The

o!Jer sibling was deceased and no cytogenetic analysis had been carried out.
Autopsy revealed that the first sibling had Type I truncus arteriosus, thymic aplasia,

and parathyroid hypoplasia, the second sibling also had Type I truncus arteriosus
accompanied by dysmorphic features and T-cell abnonnalities. The mother of both
children had no history of heart munnur, seizures, or serious infections, although on
physical examination she did have slightly dysmorphic facies and an identical
translocation to her younger child. This study provides further evidence that, in
some individuals, even when DGS is not obvious a microdeletion of 22qll may be
present (Greenberg eta/., 1984).

DGS is also closely related to Shprintzen syndrome (also known as velo-cardiofacial syndrome, VCFS) (Wilson et a/., 1992b), and the CHARGE association
(Cyran eta/., 1987). It has been surmised that VCFS is caused by a deletion of the
same gene or set of genes as DGS (Scambler, 1993). It has also been proposed that

not only do autosomal dominant DGS and VCFS have a common microdeletion, but
they are in fact all cases ofVCFS (Stevens eta/., 1990).

1,5, Yelocardiofacial syndrome (YCFS)
Velocardiofacial syndrome (VCFS) is a syndrome of multiple anomalies, including

I

cleft palate, heart malfonnations, facial characteristics and learning disabilities. It

~)
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was described in a group of 12 unrelated children by Robert Shprintzen in 1978,
although a familial case had been described previously (Strong, 1978). Since that

time Shprintzen has examined over 100 affected individuals and has documented the
phenotypes of all these cases (Goldberg eta/., 1993). Shprintzen has proposed that
most reported cases of familial DGS are in fact misdiagnosed VCFS (Shprintzen,
!994), a belief which may be justified given the phenotypic variability of VCFS.
,j

Like DGS, there is considerable phenotypic variability not only between unrelated
patients but also within families (Holder eta/., 1993). Molecular studies of VCFS

·-.1'

'

patients have shown that like DGS they also display monosomy for a region of
chromosome 22qll (Kelly eta/., 1993). Monosomy 22qll was revealed in 18

II

patients with different probes specific for 22qll, using dosage analysis in search of
~'-:•,

monosomy at this locus.

The patients tested in this study disPlayed variable

phenotypes, although they had all been previously clinically diagnosed as having
VCFS (Motzkin et a/., 1993).

Other studies have also noted extreme clinical

variability in VCFS patients and Meinecke et a/. (I 986) concluded that VCFS is

probably caused by a dominant gene with very variable expression. As a result of
this variability, patients who do not exhibit obvious symptoms, such as cardiac
defects, may not be • ·erectly diagnosed. One clinical study into VCFS surveyed 38

children, all of whom were diagnosed as having the disorder, even though 42% of the
children had no congenital heart defect.

It must be noted, however, that no

"'
f:

cytogenetic or molecular analyGis was reported for this group. It has been suggested

;_~:~
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::··.

r
• ---1

--

8

therefore that lack of cardiac defect should not deter the clinician from making a
diagnosis ofVCFS (Lipson eta/., 1991).

There is no dispute that VCFS and DGS share an aetiological connection. They both

display evidence of monosomy 22qll and have some common phenotypic fea.,Jres
(Scarobler eta/., 1992). Due to the overlap in symptoms, some if not all cases of
DGS may be misdiagnosed cases of VCFS (Goldberg et a/., 1985). Some distinct
clinical features which are specific to VCFS are not found in DGS (Driscoll et a/.,
1992b), also some researchers see DGS as a particular form of VCFS and not a

separate disordei.

There have been reported cases for example, of psychosis

associated with VCFS which is not apparent in DGS (Dunharo, et a/., 1992)
(Shprintzen eta/., 1992). Based on this evidence, DGS may be a particular form of

VCFS, however many clinicians believe that it can be diagnosed separately from
-!
-'

VCFS because of its particular combination of symptoms.

'

:·:

1.6. Possible causes ofDGS
Although the title of this condition (or conditions) has been a matter of dispute
(Lischner, 1972), it is widely agreed that the characteristic phenotype ofDGS is the
result of an abnormality in the formation of the III & IV pharyngeal pouches. An

i

J

embryological disorder of this nature, due to inadequate neural crest contribution in

j

development, is termed a neurocristopathy (Hong, 1991).

When the DGS

neurocristopathy was examined it was apparent that a number of events could occur

,.
!

'

.
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;
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during early pregnancy to cause the condition.

As well as chromosomal

abnormalities, teratogens such as retinoic acid (a synthetic fonn of vitamin A found
in acne treatments), have been linked to DGS (Lammer eta/., 1985). It has also been

J

'

'

suggested that maternal insulin dependent diabetes acts as a pathogenetic factor in
the Di George anomaly. Two infants born to diabetic mothers had apparent DGS

}'

and renal agenesis. Both mothers and their infants had normal cytogenetic
karyotypes. Molecular studies, using a probe which is believed to be specific for the
gene region deleted in DGS, failed to detect a microdeletion of chromosome 22qll
in these patients (Wilson, T. eta/., 1993).

.

')

·.\':

h·

DGS is referred to by many researchers as Di George anomaly rather than syndrome,
the term anomaly being preferred because it infers the numerous suggested
aetiologies associated with the disorder and stresses its origin as a developmental
field defect (Opitz & Lewin, 1987). It should be noted that unless DGS and Di

George anomaly are specifically distinguished from each other, essentially they can
F':·

be regarded as the same condition.

1,7. The variability of conlolenital heart defects (CHD) in DGS

Genetic defects are known to be a major cause of heart malformation (Wilson et al.,
1991). In DGS and VCFS certain types ofCHD are over-represented by comparison
with their incidence in the general population (Worthington, 1994). Conotruncal
cardiac defects are over-represented in both DGS and VCFS.

The conotruncal

j
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t
defects particular to DGS are interrupted aortic arch (type B) (JAA), truncus
arteriosus (TA), and tetralogy ofFallot (TOF). TOF is also one of the most common
forms of cardiac defect present in VCFS. Since DGS and VCFS have both been

associated with microdeletions of chromosome 22qll, it was supposed that a
deletion in the 22ql I region was also responsible for the types of cardiac defect

common to these disorders. A study to substantiate this assumption was carried out
on a group of patients with the tetralogy of Falla! defect, who had no other signs of

either DGS or v'CFS. A total of seventeen patients were tested for evidence of a
microdeletion in chromosome 22qll using restriction fragment length polymorphism
(RFLP) and dosage analysis, five of the seventeen were shown to have a 22qll
deletion (Goldmuntz eta/., I993). As well as RFLP and dosage analysis to test for

'.
'

this deletion, Goldmuntz et a/. (1993) also reported on the usefulness of FISH as a
way to determine whether families with a history of CHD have the 22q II

microdeletion. Families who have a known deletion, even if unaccompanied by
symptoms of DGS or VCFS, will be able to utilise clinical testing and genetic

counselling to determine the risk of heritability of the deletion which accompanies

..

'·'

CHD.

'1.

j

Other studies have provided similar evidence on the connection between isolated

J

!

'

heart defects and the 22ql I microdeletion. DGS was diagnosed in an infant with

T

IAA, hypoparathyroidism and low T-cell lymphocyte numbers. Two siblings had

_, _

"i

heart defects that are not common to DGS (a membranous ventricular septal defect,

_,

r

I
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and coarctation of the aorta) and neither sibling showed signs ofDGS. Chromosome

analysis of their mother, whose cardiovascular examination was nonnal, and her
three offspring with heart defects all revealed a 22q II interstitial deletion.

The

deletion was subsequently confirmed by molecular analysis (Wilson eta/., 1991).

This case promoted further study into deletions in nine families with recurrent
outflow-tract heart defects. In five of the families, chromosome 22 deletions were
detected in all of the living affected individuals, and they were also present in the
clinically normal father of a further fr :.1ily in which there were three affected

children. As a result of these studies it was proposed that deletions within band qll

of chromosome 22 are an important cause of some familial heart defects (Wilson et
a/., 1992a).

1.8 Prenatal detection ofCHD
Congenital heart defects are often diagnosed prenatally by ultrasound, and it is
normal to follow the detection of a CHD with prenatal karyotyping in order to

determine the extent of chromosomal involvement. It has been revealed by such

karyotyping that chromosome abnormalities are present in 15.4% of fetuses with an
isolated cardiac malformation and in 42.7% with an additional malformation
(Catherine eta/., 1991). In children with DGS chromosome abnormalities can prove
difficult to diagnose prenatally due to the failure of fetal blood to culture for
karyotyping. This is because individuals with DGS have a reduced number of Tlymphocytes, and since lymphocytes are the cells cuitured for karyotyping

-
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insufficient numbers may be available to analyse for a karyotype.

It has been

proposed that if a fetal blood culture cannot be karyotyped when a CHD of the DGStype is present, then fetal lymphocyte sub populations should be examined in order to

l

diagnose DGS (Catherine eta/., 1991). Although it also has been suggested that,

when a CHD is diagnosed prenatally, cytogenetic and molecular analysis of amniotic:
fluid cells or chorionic villi would be more sensitive and accurate than
characterisation of fetal lymphocyte populations (Driscoll et a/., 1991). It was
subsequently confirmed that FISH of cultured amniocytes provided an efficient and

direct method for the pre-natal detection of microdeletions including monosomy
22q 11, which was detected in two separate pregnancies by this method (Drisco11 et
a/., 1993).

Karyotyping of chorionic villi in a family with a known reciprocal balanced
translocation involving chromosomes 9 and 22, at the regions q22 and ql 1.2

respectively, revealed an unbalanced karyotype in the fetus. This arose due to an

''

adjacent-2 disjunction of the quadrivalent in the mother. The test was performed
because a previous sibling had died at age three weeks due to cardiovascular
complications.

Karyotyping of this infant revealed the same unbalanced

translocation as had previously been found in the fetus (Pivnick et a/., I 990).

Another case where an unbalanced translocation of chromosomes 9;22 was reported
also resulted in symptoms ofDGS (El-Fouly eta/., 1991).

:';.
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1.9 Prevalence ofDi Georce syndrome
The number of children affected by DGS is not readily calculated. The prevalence
has been estimated at I in 20,000, but this figure is probably an under-estimate based

only on the ascertainment of severe cases (Scambler, I993). If severe and mild cases
are included then CHD seems to be quite a common disorder with, I in I00 live
births resulting in some form of cardiac defect (Hoffman, 1990). In order to gain a

meaningful insight into the prevalence of DGS, large groups of patients and their
families will need to be assessed by clinical, cytogenetic and molecular examination.
The results of such a study will provide not only useful information on the
prevalence of DOS in the population, but also on the degree of variation in the
severity of symptoms and their aetiology.

1,10 The 2enetic aetiology ofDGS

The genetic aetiology of DOS has been attributed to a microdeletion of chromosome
22q II, in a region known as the Di George critical region (DGCR).

When

chromosome 22 is deleted in the defined region DOS results. The DOCR was first
suggested by De !a Chapelle and his colleagues (1981).

In their study, a

chromosome analysis of a large family was undertaken and some members of the
family were shown to display an unbalanced chromosomal rearrangement leading to
trisomy 20pter->20qll and monosomy 22pter->22qll. The clinical features of

trisomy 20p were already known and since they did not correspond to the features of

•'!.

' ;

•

'
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DGS (Francke, 1977), this trisomy was rejected as the cause of DGS. It was
therefore suggested that DGS was due to a monosomy of the region 22pter--+22qll
(De Ia Chapelle et a/., 1981). This hypothesis was later verified by cytogenetic
analysis of other DGS patients with interstitial deletions, del (22)(ql 1.21 ql 1.23) but
no other apparent cytogenetic abnormality (Greenberg eta/., l988a).

On the basis of these findings it was hypothesised that the DGCR lies within 22q II
(Driscoll el a/., l992a). It has subsequently been shown cytogenetically (Wilson et
a/., 1992b), and by molecular methods (Driscoll et a/., I992a), that most DGS

patients (approximately 90% as reviewed in Carey el a/., 1992) have a detectable
22qll microdeletion.

This microdeletion is often the result of an unbalanced

translocation. The specific breakpoint may be important in some cases, however the
clinical features are probably more related to the activity of the alleles for which the

-~

i

patient is hemizygous (Faed eta/., 1987). The modes of inheritance suggested for

DGS, like that of its symptoms, have been varied. Cases reported to date have most

.-

often demonstrated an autosomal dominant pattern of inheritance, although
autosomal recessive and X-linked chromosomal patterns have also been noted
(Driscoll eta/., l992a). The first reports of autosomal dominant transmission of the

Di George phenotype were made by De Ia Chapelle (1981 ), and they were
subsequently verifi•.d by Kelley et al. (1982). The ambiguity which exists with
regard to the inheritance ofDGS is partly attributable to the difficulty in diagnosing
a microdeletion.

''
.:I

Although parents and siblings may have such a chromosomal

I!.
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aberration, it is quite often missed even when high resolution cytogenetic analysis is

'

undertaken (Keppen et a/., 1988). In one family both siblings and their father bad

evidence of DGS. Their clinical features included hypocalcaemia, unusual facies,
truncus arteriosus, impaired cell mediated immunity and the father had a relatively
;·

low number ofT-lymphocytes. Chromosome banding studies nevertheless showed

\..
r

ail family members to have normal karyotypes (Rohn eta/., 1984).

Different chromosome regions have been linked to the phenotypic characteristics of
DGS other than chromosome 22qll. These aberrations are summarised in Table I.l.
In spite of the aetiological heterogeneity of DGS, evidence suggests that the most
common cause is monosomy 22qll (Greenberg, 1993).

It has been proposed,

however, that the DGS gene would be a good model for gene defects which are

likely to be affected by other genes or environmental influences, as a true polygenic
or multifactorial disorder. Due to this possible heterogeneity it has been emphasised
that other DGS loci so far suggested, such as 10pl3, must not be neglected in future
~

,,'
,;

studies (Greenberg, 1993).

I. I 1. Cytogenetic analysis of chromosomes

Human cytogenetic studies are based on the analysis of karyotypes made from

:;.

metaphase chromosome preparations. The earliest recorded attempt to study human
chromosomes using cultures of leukocytes from peripheral blood was made by
!f/

Chrustchoff and his co-workers in I 931 (Hamerton, I 97 I).
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Table I. I: The less common chromosome aberrations associated with DGS

:

'

Chromosome location

Reported by:-

isochromosome 18q,
manifests as monosomy
I 8p and trisomy I 8q

van Essen eta/. (I 993)

.·;

Comments

Clinical signs ofDGS with
holoprosencephaly and
streak ovaries
Clinical signs of DGS with
absence of thymus but
involved 22p not 22q

unbalanced paternal
translocation t(I 8;22)

Bowen et a/. (I 986)

rnonosomy 12p with
trisomy !Oq

Greenberg eta/. (I 988a)

Clinical signs ofDGS

monosomy 5p

Greenberg eta/, (I 988a)

Clinical signs of DGS

partial trisomy I q

Greenberg eta/. (I 988a)

Clinical signs ofDGS

monosomy 17p!3

Greenberg eta/. (I 988b)

Clinical signs ofDGS
This chromosomal
rearrangement has been
associated with DGS
phenotype on more than
one occasion

Greenberg eta/. (I 988a)
monosomy lOp 13

&

Monaco et a/. (I 99 I)

''
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It was not, however, untill956 that the chromosome number of humans was verified

to be 46 (Tjio & Levan, 1956). Even then the available cytogenetic techniques were

such that it was impossible to clearly distinguish individual chromosomes within a
particular group. Human metaphase chromosomes can be organised after simple
staining into seven groups (A-G) according to their relative size and centromeric
position.

Chromosome identification was altered by the advent of quinacrine

i

I

!

I\

t
,

1.'

(·

mustard staining (Q-banding) (Caspersson eta/., 1968), which allowed each hmnan

chromosome pair to be individually recognised. In order to visualise

Q~banded

chromosomes a fluorescent microscope is required. Shortly after the invention of Qbanding another type of banding technique was discovered, giemsa staining with
trypsin (G-banding), and tlus type of banding is the preferred method of staining in
most laboratories.

Although, G-banding and Q-banding give similar quality

karyotypes, G-banding is more common because it is permanent and can be detected
with a standard light microscope (Harnerton, 1971 ).
_,_;·,.,-_

s·

1.12. Production of metaphase chromosome preparations
~-

Chromosomes analysed by karyotyping are harvested from cultured cells, with a

)

droplet of cultured cell suspension fixed on to a microscope slide as a metaphase
spread. Metaphase spreads are prepared from various specimens such as, peripheral
blood, amniocytes, chorionic villi, or any tissue or cell line which is actively dividing
(Verma and Babu, 1989). The specimens are cultured and treated so that the cell

cycle is arrested at the metaphase stage of mitosis. The cells are then treated with a
i
I

', 'i

I

)

I
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hypotonic solution Q3mery, 1979). This ensures that on dropping the suspension on

to a microscope slide the chromosomes in a high proportion of the nuclei will spread.
The nuclei disperse in such a manner that the chromosomes from each nucleus
remain distinct from those in adjacent nuclei on the slide.

The subsequent

application of a fixative ensures that the cells adhere to the slide.

When the

metaphase spreads have been fixed to the slides they can then be banded.

:l

'•

'~

-·-~

As previously mentioned, DGS was found to be linked most often with an interstitial
deletion of22qll (Greenberg eta/., 1988a). Due to the small size of chromosome
22, standard synchronised G-banded metaphase spreads do not clearly define band

qll and for this reason it is necessary to produce high resolution preparations in
order to see a microdeletion in this region. This is achieved by decreasing the time
that the culture is exposed to colcemid. Colcemid, when added to chromosomes,
affects spindle fonnation and the chromosomes remain at the metaphase stage of the
cell cycle. When the chromosomes are exposed to colcemid for a relatively long
',

''
time they begin to constrict and fewer bands can be defined when stained. By

'

'

reducing colcemid exposure time the chromosomes appear to be longer and more
bands are produced, which results in suitably high resolution chromosomes (i.e., at
least 850 bands/haploid set) (Standing Committee on Human Cytogenetic

Nomenclature, 1985). It has been demonstrated that, even when metaphase spreads
are prepared at this high resolution, it may still not be possible to locate
microdeletions cytogenetically (Carey eta/., 1992). If molecular methods are not
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available, however, it has been suggested that high resolution studies of suspected
microdeletions are justified, although the number of patients shown to have an
interstitial deletion by high resolution karyotype may be low (Mascarello el a/.,
1989).

1.13, Molecular analysis of the Dj

Geor~e

critical

re~ion

(DGCR)

Only large interstitial deletions of chromosome 22 can be observed cytogenetically
with high resolution karyotypes (Greenberg et al., !988a), and so deletions of less

•

than 3-5 x 106 base pairs are not reliably detectable using cytogenetic analysis. It is

'
.,1
-~

therefore necessary to employ techniques such as in situ hybridisation (ISH) to detect
microdeletion 22q II. In one study a series of ten patients affected by DOS were
screened by high resolution banding and FISH of a cosmid probe. All ten patients

had a microdeletion of22qll by in situ hybridisation. However, only two of the ten
were suspected of having this deletion by high resolution banding (Desmaze eta!.,
!993a).
;._'

1.14. In situ hybddisation (ISH)

In situ hybridisation is based on the double-stranded nature of DNA.

When

denatured the two strands of DNA separate and then quickly rejoin (Leversha, 1993).
The principle by which ISH works is to incorporate a DNA probe during the

r

l

:j

renaturation process into the chromosomal DNA of an intact chromosome. A DNA

l

hybrid is then formed between a single strand of the probe DNA and its

t.
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complementary single strand of chromosomal DNA as they reanneal, The probe is
labelled so that when it is joined to the chromosomal DNA and forms a hybrid, a

signal of this region can be detected.
'

Initially, probes were labelled isotopically and detected by autoradiography, The

'
'

first isotopic in situ hybridisation was based on the early work of Gall and Pardue in
1969, however this techoique is techoically difficult and potentially hazardous due to

radioactivity. It is also much slower than non-isotopic in situ hybridisation (NISH),

'

!

as signals can take 2-3 weeks to be detected. Isotopic in situ hybridisation has

largely been superseded by NlSH (Lichter & Ward, 1990), In NISH, hybridisation
usually takes place overnight and the probe is detected by a reporter molecule bound
to a histochemical stain aggregate sufficiently large to permit visualisation.
f

'

Enzymes such as horse radish peroxidase will catalyse the precipitation of deposits
which can be seen with a light microscope (Leversha, 1993),

Alternatively,

fluorochromes can be linked to the probe via a reporter molecule that, after

hybridisation, binds to fluorescent affinity reage.,ts. Probes may also be directly
conjugated with fluorescent molecules, the most common of which are fluorescein
isothiocyanate, rhodamine and Texas Red (Trask, 1991), Fluorescent labels have the
added advantage that chromosomes can be simultaneously Q-banded as well as have
probes hybridised to them.
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1.15. FISH and the detection ofDGS
FISH has been successfully used to detect DGS by several research groups. Carey et

a/. (1992) were able to demonstrate that 21 out of22 patients suspected of having
DGS were hemizygous for 22q II. When this result was combined with one of their
earlier studies, 33 out of 35 DGS patients had chromosome 22qll deletions
detectable by DNA probes (Carey eta/., 1992). A similar study also using a cosmid
probe showed 10 out of 10 patients to have a detectable 22qll deletion, whereas
only two of the ten were diagnosed cytogenetically (Desmaze et a/., 1993a). A

second study by the same researchers describes the relative ordering by FISH of
cosmid loci and translocation breakpoints in the Di George syndrome critical region
(DGCR) of chromosome 22 (Desmaze eta/., 1993b). Such studies aim to define the

smallest region which can be lost and still result in DGS. As well as providing a
diagnostic tool for DGS patients, FISH can also be utilised for prenatal diagnosis and
genetic counselling (Driscoll eta/., 1993). The use of a cosmid probe in FISH has
.,,

also enabled researchers to show that similar conditions may in fact be related to
DGS. Burn et a/., (1993) showed that a cosmid probe could delineate a 22qll

deletion in the conotruncal anomaly facial syndrome.

1.16. In silu hybridisatjoo as a research tool
ISH can be used to fmd the chromosomal location of DNA probes. A probe for the A.
immunoglobulin light chain cluster (A. IGLC) constant region was hybridised to

22

chromosome preparations of two patients with DGS-related translocations.

The

results showed that the gene in question, A. IGLC, was not involved in DGS
(Cannizzaro and Emanuel, 1985). Although this study did not show the location of
the DGS gene or genes to be within the A.IGLC region, it effectively eliminated this

area from the search for such a region in 22q 11. There have been many similar
studies undertaken with respect to the physical mapping of the DGCR, which was
narrowed down to chromosome 22qll.21-tq11.23 by Fibison et a/. (1990).
Numerous DNA makers which are deleted in patients with DGS have been mapped
to the 22qll-pter region (Carey eta/., 1990), and these markers provide a basis for
adding fine detail to the proximal map of 22q II.

Other anonymous DNA markers for the DGCR have since been mapped using
hybrids from patients with DGS (Sharkey et a/., 1992). One such study (Budarf et

a/., 1992) indicated that a gene may have been isolated from the DGCR, although the

.

·:

complete sequeflce, function and development expression pattern of the gene have

;.:

.
i

not yet been determined.

One of the most recent cosmid markers, cHKAD-26

,

.'~

(Kurahashi eta/., 1994) to be assigned to the DGCR was from a genomic cosmid

library constructed from a Chinese hamster/human hybrid, this marker may prove
'
I
!

. :!

useful in the clinical diagnosis of DGS and VCFS. Another 108 cosmid markers

were regionally assigned to human chromosome 22 in the search for the DGCR
probe.

.

It is envisaged that these will be used for further investigation in the
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construction of long range physical maps and for localising genetic alterations on the

:i

chromosome (Kurahashi eta/., 1994).

1.17. The clinjcal use of jn situ bybridjsation

In situ hybridisation can be used as a clinical diagnostic tool not only for DGS and
VCFS but also for many chromosomal abnormalities.

As well as the ISH of
~-

metaphase chromosomes, interphase nuclei analysis has also been suggested. This

method is a rapid and efficient tool in the identification of trisomy 21 (Lichter et al.,
1988). 'Chromosome painting' has been recommended as a diagnostic adjunct to
classical metaphase analysis (Hulten et a/., 1991). FISH is now used in many
cytogenetic laboratories as a diagnostic tool and probes for a large number of

chromosomal abnonnalities are commercially available.

One of the most recent molecular n.~thods in the detection of specific chromosome

.

il-

regions is the 'PRINS' technique. It enables rapid chromosome identification by
oligonucleotide-primed in situ DNA synthesis.

;;;,-,

Labelled nucleotides are

incorporated directly into the DNA of cytological preparations.

!.·

The primary

advantage of PRINS over ISH is that detection takes just two hours, as compared to
an overnight reaction. For this reason the PRINS technique may well become the
preferred method in the future (Gosden and Lawson, 1994).
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II. Materials

II. 1. List of chemicals used

Chemical

Supplier

Acetic Acid (96%)

Merck

Acetic Acid Glacial

Rhone Poulenc

Laboratory Products
Agarose (DNA grade)

Progen Industries Ltd

Aluminium Sulphate

Sigma

Anti-digoxigenin-fluorescein, Fab fragments

Boehringer Mannheim

Anti-digoxigenin-POD, Fab fragmonts

Boehringer Mannhehu

Anti-fluorescein-POD, Fab fragmen!J

Boehringer Mannheim

Bam HI

Prom ega

Bacto-tryptone

Difco Laboratories

Bacto-yeast extract

Difco Laboratories

Biotin-16- dUTP

Boehringer Mannheim

Benzyl Penicillin (600mg/vial)

CSL (Commonwealth
Serum Laboratories)

Bovine Serum Albumin (lyophilized powder)

Sigma
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Bromophenol blue

Sigma

Caesium Chloride (dihydrate)

Sigma

Chlorofonn

AualaR0 BDH

Colcemid (Gibco BRL)

Life Technologies

CuS04

Sigma

DABco•

Aldrich

2' -Deoxycytidine

Sigma

DePeXmounting medium 'Gurr'®

AualaR0 BDH

Dextran Sulphate

Phannacia

3,3 '-Diaminobenzidine (powder)

Sigma

3,3' -Diaminobenzidine Sigma fastTM(tablets)

Sigma

DIG DNA labelling and detection Kit-

Boehringer Mannheim

(digoxigenin-11-dUTP)
Dimethyl fonnamide

AualaR0 BDH

DNA (from herring spenn)

Boehringer Mannheim

EcoRI

Promega

Ethanol

.AualaR® BDH

Ethidium Bromide

Sigma

Ethylenediaminetetraacetic acid Disodium Salt (EDTA]

Sigma

Etylene glycol (ethanediol)

Sigma

Fetal bovine serum (Gibco BRL)

Life Technologies

Fluorogreen (fluorescein-11-dUTP)

Amersham
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Fonnamide (redistilled)

Progen Industries Ltd

Giemsa' s Azur~eosin~methylene blue

Merck

Glucose

AnalaR®BDH

Haematoxylin

Sigma

HCl

AnalaR®BDH

Heparin (I OOOunits/ml)

CSL (Commonwealth
Serum Laboratories)

Hind III

Promega

Human COT-I™ DNA (Gibco BRL)

Life Technologies

HybondN+

Amersham

Hydrogen Peroxide solution (-30%)

AnalaR®BDH

8-Hydroxyquinoline

AnalaR®BDH

iso-amyl alcohol (Univar)

Ajax Chemicals

Kanamycin monosulphate

Sigma

K 2HP04

AnalaR®BDH

L-glutamine (Gibco BRL)

Life Technologies

Lithium Chloride

Sigma

Lysozyme

Sigma

2-mercaptoethanol (also

~-mercaptoethanol)

Bio-Rad

Methanol

AnalaR®BDH

Mixed bed ion exchange resin

Bio-Rad

NaCl

AnalaR®BDH
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Na2HP04

AnalaR"BDH

NaOH

AnalaR"BDH

Nick Translation kit™

Boehringer Mannheim

N-laurylsarcosine blocking reagent

Boehringer Mannbeim

OptiMEM" I (reduced serum medium)

Life Technologies

Phenol

Progen Industries Ltd

Phytohaemagglutinin P

Difco Laboratories

Polaroid T667 film

Kodak®

Potassium Acetate

AnalaR® BDH

Propan-2-ol (Isopropanol)

AnalaR" BDH

Propidium Iodide (95-98%)

Sigma

Proteinase K

Promega

Restriction enzyme lOx buffer (B, C & H)

Promega

RNase A

Sigma

Streptavidin-fluorescein

Boehringer Mannheim

Streptomycin Sulphate

Sigma

Sodium Citrate

AnalaR" BDH

Sodium Dodecyl Sulphate [SDS]

Bio-Rad

Sodium Iodate

Sigma

Thymidine

Sigma

TRIZMA" base

Sigma

TWEEN"20 [Poly(oxyethylene),-sorbitan monolaurate]

Boerhringer Mannbeim
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Westart cement

Jacksons, Subiaco, WA

Whatman'" Filter paper #I

Selby

Xylene Cyanole F'P (Acid blue)

Sigma
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11.2.

Rea~ents

in use

Anti-fade mountin(i! media

Tris·CJ 20 mM pH 7.5

I part

Glycerol (containing DABCO 2%)

9 parts

To make glyceroVDABCO:
Dissolve 360mg ofDABCO into 18m! of glycerol at 70°C for 5 minutes.
To make antifade:
Add 2m! of Tris'Cl 20 mM (pH 7.5) to 18m! of glycerol/DABCO mixture.
Mix on wheel for 2 hours, then store at 4°C.

(Laboratory Manual, Dept. of Cytogenetics and Molecular
Genetics, Adelaide Children's Hospital, SA. -FISH technique)

Buffer# 1 (For Minipreparations of DNA)
50mM glucose
25mM Tris-Cl (pH 8.0)
lOmM EDTA (pH 8.0)
The above solution is prepared in batches of 500ml, it is then autoclaved for 15
minutes at JO!b/sq.in. on liquid cycle, and stored at 4°C.
(Sarnbrook eta/., 1989, p. B.22)
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Buffer# 2 (For Minipreparations of DNA)
0.2M NaOH (freshly diluted from 10M stock)
1%SDS

Buffer stored at room temperature
(Sambrook eta/., 1989, p. B.22)

Buffer# 3 (For Minipreparations of DNA)

5 M potassium acetate

60ml

glacial acetic acid

11.5ml

H2 0 (double distilled)

28.5 ml

The resulting solution is 3 M with respect to potassium and 5 M with respect to

acetate.
(Sambrook eta/., 1989, p. B.22)

Dejonised Fonnamjde

Fom1amide (redistilled)

500ml

Mixed-bed ion exchange resin

25g

Place formamide and resin in a dark bottle on a magnetic stirrer for at least one hour.
After this time filter formarnide twice through Whatman filter paper #I and store in
aliquots of 50ml at -20°C until needed. [NB. formamide is deionised when there is

no yellow colour in it and some of the resin remains blue.]
(Sambrook eta/., 1989, p.l.l 02)
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0.5 MEDIA (pH 8.0)
Disodium ethylenediaminetetraacetic acid (EDTA)

186.lg

H20 (double distilled)

800ml

Add water to EDTA and stir vigorously on a magnetic stirrer. Adjust the pH to 8.0
with NaOH (EDTA will not go into solution until pH is adjusted). Dispense solution
into lOOm! aliquots and sterilise by autoclaving (15 minutes at IOlb/sq.in. on liquid
cycle).
(Sambrook el a/., 1989, p.B. II)

Ethidjum Bromide
Ethidium Bromide

5.0g

Double distilled water500ml

Add ethidium bromide to water and stir on magnetic stirrer for several hours un~il the
dye had dissolved. Store at room temperature in a dark bottle. NB: Gloves and
mask should be worn when handling ethidium bromide.
(Sambrook eta/., 1989, p. B. II).

Gill's Haematoxylin (1.5 x strenf>lh),
To make 1.5L:
Ethylene glycol (ethanediol) 375m!
Haematoxylin

4.5g

Sodium Iodate

0.45g
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Aluminium Sulphate

39.6g

Glacial Acetic Acid

30m!

Double-distilled water

1080ml

All of the reagents are mixed for at least 1 hour before the glacial acetic acid is

added. This solution is stored at room temperature.
(Laboratory maoual of Histopathology Department at the University of Western
Australia, Department ofpathology).

Hybridisation buffer (to check the labelling of probe).
Dilution ofthe following reagents is made into SxSSC

N-laurylsarcosine Blocking reagent

5%w/v

(Boehringer Maonbeim)
Sodium salt

0.1% w/v

SDS

0.2%w/v

This solution is cloudy when made and it is stored at 4°C.
(Karen Smith, University Department ofpathology UWA. Personal correspondence).

"Kevit's" Hybridjsation Mix.
To make lOOm!:

Dextrao sulphate (10%)

lOg

20xSSC

!Oml

Formamide-deionised (FA)

50ml

l-
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TWEEN"20 (0.1 %)

O.lml

Double distilled water (ddH20)

39.9ml

Mix FA, SSC, and ddH20, pH to 7.0.

Add dextran sulphate and stir at room

temperatore for 1-2 hours. Remove from stirrer and add TWEEN®20, roll to mix.
Aliquot useful lots into Eppendorf tubes (eg.

100~1)

and store at -20°C. Discard

unused portion once thawed.
(Laboratory Manual, Dept. of Cytogenetics and Molecular
Genetics, Adelaide Children's Hospital, SA. -FISH technique)

J;B Agarose

First prepare LB liquid media and then add agarose.
LB liQllid Medium (Luria-Ber/ani Medium):

Per litre:
To 950ml of double distilled water (ddH2 0), add:
Bacto-tryptone

10 g

Bacto-yeast extract

5g

NaCl

lOg

Shake until the solutes have dissolved. Adjust the pH to 7.0 with 5 N NaOH
(- 0.2ml). Make up to a final volume of !litre with dd H20. Sterilize by autoclaving
for 20 minutes at 15lb/sq.in. on liquid cycle.
To prepare LB agarose make LB medium from the recipe above. Just prior to
autoclaving add one of the following:
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!5g/L ofagarose for plates or 7g/L for top agar.
To sterilize autoclave as above. Before pouring plates allow agarose to cool to -

50°C add any heat labile substances at this temperature (eg. antibiotics).
(Sambrook eta/., 1989, p. A.! & A.4)

Lithium Chloride (LiCI) for random primed labelling reaction

.,

'

4M LiCI solution is used in the random primed method, however
3M sodium acetate or

-·:

3M sodium chloride may be substituted for LiCI.
(Boehringer Mannheim, The DIG system user's guide for filter hybridisation, p. 7)

Loadina buffer (for electrophoresis gels)
6x Buffer type Ill

0.25% bromophenol blue
0.25% xylene cyanole FF
30% glycerol in water

This buffer is stored at 4°C.

(Sarnbrook eta/., 1989, p.6.12)

Opti-MEM (Blood culture medium)
To lOOm! of OptiMEM® 1 add by sterile technique:i'

:
i

,j

L-glutamine

!.Om!

Penicillin and Streptomycin !.Om!
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Heparin (1 OOOU/ml)

!.Om!

Phytohaemagglutinin

!.25m!

Fetal Bovine serum

5.0ml

Store medium at 4°C, after the above reagents are added to OptiMEM discard

unused portion within 2 weeks.
(Cytogenetics Laboratory manual, p.64. SHLS, WA).

-!

Phosphate Buffered Saline (l'BS)
NaCl

8.0g

KCl

0.2g

Na2HP04

1.44g
0.24g

Dissolve the above in 800ml of double distilled water (ddH,O). Adjust the pH to 7.4
with HCl and add ddH2 0 to make a final volume of 1 litre. Sterilise by autoclaving

for 20 minutes at lSib/sq.in. on liquid cycle, then store at room temperature.
(Sarnbrook eta/., 1989, p. B.l2).

Phenol (equilibrated)
Before use phenol must be equilibrated to a pH >7.8.
Phenol prior to equilibration should be stored at -2G°C. To equilibrate:

I. Remove phenol from freezer, allow it to warm to room temperature and
melt it at 68°C,

j

'

·_.;

'.1
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2. Add hydroxyquinoline at a final concentration of 0.1 %, this gives the
phenol a yellow tinge and allows rapid identification of the organic phase.
3. To the melted phenol add an equal volume of buffer [O.SM Tris'Cl pH 8.0

at room temperature]. Stir the mixture on a magnetic stirrer for 15 minutes.
AHow the two phases to separate and aspirate as much as possible of the
upper aqueous phase.
I
- .;

4. Repeat step 3. as many times as is required to get phenol to a pH of >7.8
(measure pH with pH paper).

_,,

5. After phenol is equilibrated and final aqueous layer is removed, add 0.1
volume of O.IM TrisCl (pH 8.0) containing 0.2% P-mercaptoethanol.
Phenol solution is stored in this form under 1OOmM TrisC1 (pH 8.0) in a dark
bottle at 4•c for up to 1 month.
(Sambrook el a/., 1989, p. B.4).

Phenol:Chlorofonn:lsoamyl alcohol(25 :24:1)
Phenol is equilibrated as above and added in equal parts to cbloroform:isoarny1
alcohol (24:1). Neither chloroform nor isoamyl alcohol require treatment before use.
The pheool:chloroform:isoarnyl alcohol mixture is stored under 1OOmM Tris'CI (pH
8.0) in a dark bottle at 4•c for up to 1 month.
(Sarnbrook el a/., 1989, p. B.S).
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RNaseA
Sodium acetate O.OlM (pH 5.2)
Tris·CllM

Dissolve RNase A to a concentration of !Omg!ml in sodium acetate. Heat to 100°C
for 15 minutes, allow to cool and adjust the pH by adding 0.1 volumes of lm Tris'Cl
(pH 7.4).

Dispense into 500J.1l aliquots and store at -20"C.

For RNase slide

preparation prior to in situ hybridisation dilute RNase A to a concentration of
1OOJ.!g/ml with sterile water or 2xSSC.
(Sambrook eta/., 1989, p. B.l7).

Scott's tap water substitute.
To make 2litres:

Sodium bicarbonate

7.0g

Magnesium Sulphate

40g

Crystal thymol

3-6 crystals

Tap water

approximately 2 litres

All reagents are mixed in 1.8 litres oftap water until completely dissolved, then the

final volume of the solution is made up to 21itres.
(Laboratory manual of Histopathology Department at the University of Western
Australia, Department of Pathology).
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Sodium dodecyl sulphate (SDS)
SDS (electrophoresis grade)

IOOg

Double distilled water (ddH20)

I litre

Dissolve SDS in 900ml of ddH 20. Heat to 68'C to assist dissolution and adjust pH
to 7.2 by adding a few drops of c.HCI, make up to a final volume of I litre and store

at room temperature.
(Sambrook eta/, 1989, p. B. 13).

STE buffer
NaCI (0.1 M)
Tris"CI (!OM, pH 8.0)
EDTA (lmM, pH 8.0)
Mix NaCI, Tris'CI, and EDTA solutions of the above concentrations to final pH of
8.0. Sterilise by autoclaving for 20 minutes at !Sib/sq.in. on liquid cycle. Store at

room temperature.
(Sambrook eta/., 1989, p. B.I3).

20XSSC
NaCI

175.3g

Sodium Citrate

88.2g

Double distilled water (ddH20)

"'I litre
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Dissolve NaCI and sodium citrate in 800ml of ddH2 0 and adjust pH to 7.0 with I OM
NaOH, make up to a final volume of I litre with water. Sterilise by autoclaving for

20 minutes at lSlb/sq.in. on liquid cycle. Store at room temperature.
(Sambrookelai., 1989,p. B.13).

TAEbutfe1
SOx stock solution

Tris base

242g

glacial acetic acid

57.lml

0.5M EDTA (pH 8.0)

lOOm!

lx buffer contains 0.04M tris acetate and O.OO!M EDTA
(Sam brook eta/., !989, p. B.23)

Tris- buffered saline (TBS)
NaCI

8.0g

KCI

0.2g

Tris base

3.0g

Dissolve the above into 800ml of double distilled water (ddH2 0), and adjust pH to
7.4 with HCI. When desired pH is achieved make up to a final volume of I litre with
ddH2 0. Sterilise by autoclaving for 20 minutes at 15lb/sq.in. on liquid cycle. Store
at room temperature.

(Sambrook eta/., 1989, p. B.l4).
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IE Buffer (pH 7.4)
I OmM Tris·ct pH 7.4
lmM EDTA pH 8.0

This buffer is stored at room temperature.

(Sambrook eta/., 1989, p. B.20).

Iris-HCl buffer

Tris base

121.1g

Double distilled water (ddH20)

"'lL (less due to addition ofHCl)

Add Tris base to 800ml of water and adjust pH by adding concentrated HCl:eg.

pH

c.HCI

7.4

70ml

7.6

60ml

8.0

42ml

Make final adjustments to pH when solution is at room temperature, make up to final
volume of 1 litre. Sterilise by autoclaving for 20 minutes at 15lb/sq.in. on liquid
cycle.

Store at room temperature. [NB the pH of Tris solutions is temperature-

dependent and decreases approximately 0.03 pH units for each 1°C increase in

temperature].
(Sambrook eta/., 1989, p. B.l4).
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2xYTmedh:m
Per Litre:
To 900ml of double distilled (ddH,O), add·.
Bacto-tryptone

16g

Bacto-yeast extract

lOg

NaCl

Sg

Shake until the solutes have dissolved. Adjust the pH to 7.0 with 5 N NaOH. Make
up to a fmal volume of llitre with dd H00. Sterilize by autoclaving for 20 minutes at
15lb/sq.in. on liquid cycle.

2~YT

Agarose

To prepare 2xYT agarose make 2x YT medium from the recipe above. Just prior to
autoclaving add one of the following:
15g/L ofagarose for plates or 7g!L for top agar.

To sterilize autoclave as above. Before pouring plates a11ow agarose to cool to 50°C add any heat labile substances at this temperature (eg. antibiotics).
(Sarnbrook eta/., 1989, p. A.3 & A.4)
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III. Methods

III. 1. Preparation of a cosmjd for

labellin~

III. I .i). Chromosome 22 specific cosmid probes
Two different cosmid probes were used for in situ hybridisation. The first, cosmid
Cl79, was obtained from Prof. J Burn of the Department of Human Genetics at the
University of Newcastle upon Tyne, U.K. It is a unique copy probe for a single
repeat region of the genome which corresponds to chromosome 22q 11. This region
is believed to be deleted in affected individuals with DGS. The other cosmid probe
used was D22S75, and it too is a marker within the DGCR.

The probe was

purchased from ONCOR®, Gaithersburg, USA. The commercial probe is prepared

for in situ hybridisation prior to purchase.

It is labelled with digoxigenin and

packaged in a hybridisation solution as single stranded DNA. This means that it

requires no labelling or denaturation before hybridisation, unlike the donated probe.

Ill. l.ii). The preparation of non-commercial cosmid probes

Cosmid C179 arrived from the U.K. in a kanamycin-resistant strain of enterobacteria,
as a stab culture.

(Despite repeated queries to the donor laboratory for further

details, infonnation on the provenance of the probe and the host organism were not
forthcoming).

To isolate the cosmid probe from the stab for use in an in situ

hybridisation experiment, the bacteria was streaked on to an agar plate, containing
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kanamycin, and allowed to grow.

A single colony was then amplified in the

appropriate medium. Once amplified, the cosmid was extracted from the bacteria by
alkaline lysis and purified.

Cosmid Cl79 was isolated and purified using this

method by Dr. E. Edkins at the Molecular Biology Department of Princess Margaret
Hospital for Children('/{A). After the probe DNA was extracted and purified, it was

ready for in situ hybridisation with metaphase chromosome spreads. A small-scale
preparation (termed a mini-preparation, Sarnbrook et a/., 1989 p.l.25) was first

attempted, to ensure presence of the desired cosmid in the bacteria. When this had

been confirmed, a large scale version was performed.

III.l .jii). Isolation of cosmjd DNA from bacteria (Smale-scale preparation of C179)
DAY!:
A loop of cosmid C 179 was first streaked on to a 2xYT agarose plate by sterile
technique. The agarose contained kanamycin at a concentration of !Of!g/ml. To
pour the plate, 2xYT agarose (see 'II.2. Reagents in use') was autoclaved and

allowed to cool in an incubator to around 50°C. This temperature is sufficiently cool
to permit the addition of antibiotic to the agar without altering the molecular
structure of the antibiotic and destroying its effect. After the agarose had been mixed
with the kanamycin, the plates are poured and left to set. A loop of the kanamycin-

resistant bacteria which contains C179 could then be removed from the stab culture
and streaked onto a 2xYT agarose plate. The plate was then inverted and incubated
at 37'C overnight.
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Ill. l.iv). Amplification of cos mid DNA
DAY2:
To culture the bacteria containing Cl79, a single colony of Cl79 was transferred
from the agarose plate into 2m! of2xYT medium containing kanamycin (I 0J.lg/ml) in
a loosely capped 15m! tube. The tube was again incubated at 37'C overnight with

vigorous shaking.

DAY3:

An aliquant of culture (l.Sml) was pipetted into a microcentrifuge tube with any
surplus culture stored at 4 'C. The tube was centrifuged at 12 OOOg for 30 seconds at

4 °C in a microfuge. The supernatant was removed from the tube by aspiration and
inverted on to a paper towel for 2 minutes, this ensured that the bacterial pellet was
as dry as possible. The pellet was resuspended by vigorous vortexing in 100}ll of ice
cold Buffer #I (see '1!.2. Reagents in use' for Buffers #1, #2 & #3).

Freshly

prepared Buffer #2 (200J.ll) was added, the cap on tube replaced tightly, and the
contents mixed by rapidly inverting the tube 4-5 times. The tube was then placed on
ice and !SOJ.!I of ice cold Buffer #3 added. The tube

was vortexed gently for 10

seconds to disperse Buffer #3 through the viscous lysate, and placed back on ice for
3-5 minutes. After this intervai the tube was centrifuged at 12 OOOg for 5 minutes at

4 °C in a microfuge and the supernatant transferred to a fresh tube.
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III.l.Y). Precipitation ofcosmjd DNA

The DNA was precipitated with 2 volumes of ethanol at room temperature and the
tube mixed by vortexing. The mixture was allowed to stand at room temperature for
2 minutes, and the tube then centrifuged at 12 OOOg for 5 minutes at 4°C in a

microfuge. The supernatant was removed by gentle aspiration and the tube allowed
to stand in an inverted position on a paper towel to allow all of the fluid to drain
away.

The DNA pellet was rinsed with lml of 70% ethanol at 4'C and the

supernatant removed as before without disturbing the pellet. The pellet was allowed
to dry at room temperature for 10 minutes and then redissolved in SOJ.!l of TE buffer
(pH 8.0) containing 20JJgiml of DNAase free RNase A. After vortexing briefly the
DNA was stored at -20'C.

III.l.yi).

Determination of the concentration and purity of cosmjd DNA by the

absorbance method
To measure the abso.oance of the DNA sample at a wavelength of 260nm and
280nm, a I :2 000 dilution of the DNA sample was made in sterile water. The
spectrophotometer was blanked with sterile water at both wavelengths and the

absorbence of the sample measured. The concentration of the DNA in the sample
could then be calculated with the use of a software packaged linked to the

spectrophotometer.
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III. I.vii). Verification of presence of cosmid DNA
A sample ofcosmid C179 DNA which bad been extracted from the bacteria by mini-

preparation, was run on an agarose mini~gel to verify the presence of insert DNA and
to determine if any contamination was present. An agarose gel (0.8% in TAE buffer)
was poured on to a mini-gel tray, a small toothed comb inserted and the gel allowed
to set for 10 minutes. When set the comb was removed and the DNA sample to be

tested was loaded into the one of the wells along with markers of known size in the
adjacent wells. The gel was run at a constant 100 Volts for I hour. It was then
removed from the gel tray and washed in ethidium bromide with agitation for I 0
minutes. "The gel was then visualised on a fluorescent (UV) light box, photographed
and the photograph then analysed, the distance that the DNA travelled through the

gel is indicative of its fragment size when compared to the size of the known marker
(in this case'/.. Pst 1). The un-cut probe DNA purity could be estimated by comparing
the number of bands which appear in the probe DNA lane to those of a known pure

control sample photograph.

This comparison was usually made between the

photographs of the control and the tested DNA.

III.l.yiji). Larfi:e scale preparation ofcosmjd DNA

When the cosmid DNA had been isolated by mini-preparation, a large scale or what
is termed a maxi-preparation was set up. This preparation is a modified version of
the alkaline lysis mini-preparation method (Felliciello and Chinali, 1993), and it
yields a greater volume of probe DNA. The protocol for this procedure was;
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DAY!:
A single colony of kanamycin-resistant bacteria containing Cl79, was transferred
into 500ml of 2xYT media (I O~g/ml kanamycin) in a 2 litre capacity conical flask.

The flask was incubated overnight at 37°C with vigorous shaking.
DAY2:
The contents of the flask were transferred into 2 centrifuge bottles (250m!) and spun
at 4000g in a Sorvall GS3 rotor for 15 minutes at 4 •c.

The supernatant was

discarded and the bottles allowed to drain in an inverted position on paper towels.
The bacterial pellets in each bottle were then resuspended in 50ml of ice-cold STE
buffer. After mixing the bottles were centrifuged at 4000g in a Sorvall GS3 rotor for
15 minutes at 4"C. The supernatant was discarded and 9ml of ice-cold buffer #I
added, the bottles were then stood at room temperature for 5 minutes before 20m! of
fl·eshly prepared buffer #2 was added. The caps on the bottles were replaced tightly,
and they were then inverted several times. Ice-cold buffer #3 (!Om!) was added to

the bottles, they were shaken vigorously, and stood on ice for 10 minutes. The
resulting lysate was centrifuged at 4000g for 15 minutes at 4"C. After this interval
the supernatant from both bottles was filtered through 4 layers of cheesecloth into a
single Oak Ridge tube and centrifuged at 5000g for 15 minutes at room temperature.
The supernatant was carefully decanted from the tube and the pellet and the walls of

the tube were rinsed in 70% ethanol at room temperature. All ethanol was drained
from the tube by inversion for several minutes on to a paper towel, after which time
the pellet was Jisoolved in 3m! ofTE buffer (pH 8.0).

-~
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The Cl79 cosmid DNA was then purified by equilibrinm centrifugation in CsCI-

ethidium bromide gradients. After isolation, the purity and concentration of the
probe were tested by the same methods as described in the small-scale preparation of
probe DNA.

Ill.2.

Labellin~ ofcosmjd

DNA

Jll.2.i). Methods oflabellin~ cosmjd DNA

There are three different methods of labelling cosmid DNA for use with in situ

hybridisation. These are the direct, nick translation, and random priming methods.
Each is outlined below:11!.2.j),a. Fluorescein direct-labelling method

This method labelled the DNA directly, i.e., biotin or digoxigenin were not required.
The fluorescein was incorporated into the cosmid DNA, rather than attached to a
hapten or reporter molecule. The DNA was diluted in sterile water to the desired

concentration. Then, using a nick translation kit, the fluorescein was incorporated
into the cosmid DNA. The tubes from the nick translation kit were thawed and then
placed on ice. It should be noted that Klenow enzyme must be kept at -20'C, to

protect its activity. Once the rest of the kit had thawed, nucleotides and water were
added to the DNA according to the following protocol:
Cosmid C 179 (l j.!l) at a concentration of I 00 ng/fil was placed into a clean
microcentrifuge tube, to which the following were added:

51

IOfil dATP, lOfil dCTP, lOfil dGTP, 2fil dTTP, lfil ofFluorogreen (always kept

in dark) (Amersharn), llfil of sterile water (to make up to a final volume of 50f!l)
aod 5fil of enzyme directly from the freeze;, The tube was then centrifuged in a
microfuge at 12 OOOg for 20 seconds. The tube was incubated for 4 hours at l5°C
aod the reaction stopped by the addition of 5fil of 0.2 M EDTA. The labelled probe
was then pipetted into IOfil aliquots and stored in the dark at -20°C.
111,2.i).b. Nick translation

An aliquot of extracted C 179 was sent to the Department of Cytogenetics and
Molecular Genetics at the Adelaide Women's aod Children's Hospital. This sample
was labelled by nick-translation using the method developed by David Ward and coworkers at Yale University (Langer et a/., 1981), as described below:

Labemmi reaction for nick~translation:The following reagents were mixed in an Eppendorf tube, 5J.ll of IOx concentration
nick-translation buffer (0.5M Tris-HCl; pH 7.8, 50mM MgCl2 , 0.5mg/ml BSA,
nuclease free), 5f!l of IOOmM Dithiothreitol (DTT), 4fil of deoxynucleotide
triphosphates (0.5mM dATP, dGTP, dCTP, each), lfil of 0.5mM dTTP, 2f!l of !mM
Biotin-16-dUTP (Fluorescein or digoxigenin could alternatively be used), lfig of
Cl79 probe, lfil ofDNAase I (l 000 times diluted from lmg/ml stock) and 10 urtits
(l fll) of DNA polymerase I. The mixture was made up to a final volume of 50 fil

with sterile water and after mixing was incubated for 2 hours at l5°C. The reaction
was stopped by the addition of 5fil 0.5M EDTA (pH 7.4). The DNA was then
purified by Sephadex G-50 chromatography using a pasteur pipette column,

,.i
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equilibrated with !OmM Tris-HC!, ImM EDTA and previously flushed with 0.1%

"l

SDS (to prevent non-specific binding). The high molecular weight DNA eluted in
the second 600 ftl; this fraction was collected and stored at -20'C.

lll.2,i),c. Rand9m priming metbod oflabellin~ DNA
This third method· was carried out on a portion of the extracted cosmid probe. In
each reaction between 3ftg to lOng of DNA could be labelled.

The DNA

concentration of C I 79 was 0.1 ftg/fll and I O~tl was used i.e., in this instance I flg of
DNA was labelled. The DNA was first denatured in an Eppendorf tube with a hole
pricked in its lid, by heating it in a boiling water bath (I OO'C) for I 0 minutes. It was

removed from the water bath and immediately placed on ice for 5 minutes.
The following reagents were then added to the tube on ice;
mixture,
19~tl)

2~tl

and

of dNTP mixture,

l~tl

5~tl

2~tl

of hexanucleotide

of nuclease-free water (to make up to a volume of

of Klenow enzyme, which resulted in a total tube volume of 20ft!. It

was ensured that the cap was firmly fastened on to the tube, the tube was briefly
vortexed and then centrifuged in a microfuge at 12 OOOg ("' 10-20 seconds). The

tube was incubated overnight in a waterbath at 37°C. The next day the reaction was
stopped by the addition of 2~tl of 0.2 M EDTA (pH 8.0). The labelled DNA was
precipitated with

2~tl

of 4M LiCI and

60~tl

of pre-chilled absolute ethanol (-20'C).

The tube was well mixed and left for 1 hour at -70'C, then centrifuged for 5 minutes
at 12 OOOg (room temperature) and the supernatant removed. The pellet was washed
with cold (-20'C) 70% ethanol, and dried under a vacuum to zero volume. The DNA
was dissolved in 50ft! ofTE buffer (pH 8.0) at 37'C and then stored at -20'C.

''·
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III.2.ii). The reporter molecules used to label cosmjd probe
As previously stated {p20), probes need to be labelled either directly or with a

reporter molecule prior to use for in situ hybridisation reactions. To directly label
Cl79 Fluorogreen® (fluorescein-12-dUTP) from Arnersham was used, the probe was

labelled in accordance with the manufacturer's recommendations using a nicktranslation kit. This type of kit was also used to label Cl79 with biotin-16-dUTP.

Biotin acted as a reporter molecule (or hapten), it was incorporated into the probe
DNA and detected by affinity cytochemistry. In the case of biotin-labelled probes,

avidin or streptavidin had a high binding capacity to biotin and were used to detect
its presence (Langer et a/., 1981 ). The second type of hapten used was digoxigenin11-dUTP (DIG), Cl79 was labelled with this molecule by the random prime method.
Hybridised DIG probes are detected by high affinity anti-digoxigenin antibodies

which are conjugated to enzymes.

III.2.iii). Confirmation of probe labellin2
To confirm that the probe had been labelled, a 5 fll aliquot was hybridised to a piece
of nylon membrane and detected by the antibody to the label conjugated to an
enzyme; Cl79labelling with DIG was confirmed by this method:
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DAY!:
Unlabelled CI79 (21-'1) was pipetted into an Eppendorftube and 2111 of unlabelled
salmon sperm DNA into another. The contents of both tubes were denatured by

boiling in a waterbath at 100°C for 10 minutes, then immediately removed from the
waterbath and placed on ice. A piece of nylon membrane (Amersham Hybond N\

was cut to approximately 2.5 x 5.0 em and a small nick removed from one comer of
the membrane, below which a cross was drawn with a pencil (see figure IV.l). This
is to enable the DNA spots which are loaded on to the membrane to be distinguished
from one another. Two aliquots of Cl 79 were loaded onto the membrane (i!ll each)

along with two lots of salmon sperm DNA, so that there were 4 separate dots of
DNA. The position of each dot of DNA relative to one another was recorded. The
DNA was then bound to the membrane by heating at 62°C for I hour. DIG-labelled
Cl 79 (51-'1) was pi petted into a microfuge tube, denatured by heating to 100°C in a

boiHng water bath for 10 minutes, and immediately placed on ice. The membrane
was put into a hybridisation bag with 1-2 ml of hybridisation buffer (see 11.2.
Reagents in use), containing 51-'1 of denatured DIG-labelled CI 79. The bag was

sealed making sure that there were no air bubbles, and the membrane hybridised
overnight in a water bath set to 68°C.
DAY2:

The membrane was removed from the hybridisation bag and washed with agitation
as follows:
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2xSSC; 0.1% SDS for 2x5 minutes at room temperature, then O.lxSSC; 0.1% SDS

for 15 minutes at room temperature. The hybridised DNA on the membrane was
then detected by the following protocol:
The membrane was washed briefly (2 minutes) in buffer #!(from Boehringer
Mannheim label!ing kit; containing IOOmM maleic acid, !50mM NaCI pH 7.5) with
agitation. It was then incubated in buffer #2 (also from the kit; I% blocking reagent

in buffer #1) for 30 minutes. The membrane was washed for a second time in buffer
#I for 2 minutes with agitation. The antibody conjugate (vial 8 from kit; anti-DIG
alkaline phosphatase) was diluted to a concentration of 1:5000 in buffer #I i.e.,

4~1

of anti-DIG alkaline phosphatase is mixed with 20 ml of buffer #I. The membrane

was incubated with the diluted antibody conjugate at room temperature for 30

minutes. It was then washed twice in buffer # 1 at room temperature for 15 minutes
each with agitation to remove unbound antibody. After washing, the membrane was
equilibrated for 2 minutes in 20 ml of buffer #3 (from kit; IOOmM Tris-HCI, pH 9.5;
100 mM NaCI, 50 mM MgCI2). The following solutions were mixed to make the
colour solution just prior to use; I 0 ml of buffer #3, 45ft] of NBT solution (vial 9
from kit which contained 75mg/ml nitroblue tetrazolium salt in 70% (v/v)
dimethylfonnarnide),
50mg/ml

35~1

ofX-phosphate solution (vial!O from kit which contains

5-bromo-4-chloro-3-indolyl

phosphate,

toludinium

salt

in

100%

dimethylfonnamide). The membrane was incubated with 10 ml of colour solution
whilst sealed in a darkened box.

The colour precipitate which demarcates the

hybridisation areas on the membrane, usually formed within 10-30 minutes and
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continued forming for 16 hours. When the required intensity had formed the reaction

was stopped by washing the membrane in approximately 10 ml of TE buffer at pH
8.0 (buffer # 4 in kit). A photocopy or photograph of the membrane was taken to

create a permanent result, the membrane was then dried and sealed in a plastic bag.
The colour of the precipitate faded upon drying but it could be recovered by wetting

the membrane in buffer# 4.

111.3. Pre.paratjon of metaphase chromosome spreads

Jll.3.i). Collection of peripheral whole blood
Peripheral whole blood (l-2ml) was taken by veno-puncture from each patient, then
placed into sterile Sml vials each containing O.lml of heparin (lOOOunits/ml) and the

specimens sent to the Cytogenetics Department at State Health Laboratory Services.

Heparin was used because it is an efficient anticoagulant which did not interfere with
lymphocyte culture.

IU.3.ii). Culturing of blood. syncbronisatjoo of cell cycle and arrest at metaphase
Throughout the whole of the culturing process, specimens were handled by sterile
technique. The tubes were first 'set-up', i.e., 3 sterile tubes (10 ml capacity) of blood

were set up on each patient, 2 were processed as synchronised cultures and 1 as a
high resolution c>Jlture. All 3 of the tubes received 0.25 ml of whole blood and
S.Oml of Opti-MEM supplemented medium, the caps were put on the tubes loosely
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and they were incubated at 37°C in a C02 enriched environment for 48 hours. After
which the tubes were removed from the incubator and IOO!Jl of thymidine, was
added by sterile technique to block DNA synthesis. The tubes were returned to the

incubator with the same conditions as before for a further 17 hours. After this time
IOOJ.!l of deoxycytidine was added to release the block on DNA synthesis and the

cells in culture were allowed to resume the cell cycle in the incubator at 37°C.
Colcemid (50!Jl) was added after4

1
/2

hours to the 2 tubes which were to be used for

synchronised karyotyping and in situ hybridisation, they were then incubated for a
further 30 minutes prior to the harvesting the cells. The tube which was to be used
1

for high resolution (HRS) karyotyping remained in the incubator for 4 hours and 50
minutes before it too received SOj.tl of colcemid.

It was then returned to the

incubator for 10 minutes and the cells were harvested at the same time as those of the
i

synchronised cultures.

i'

j

i

'
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III.3.iji). Harvesting of lymphocytes and fixation of cell suspension
The following reagents were needed for harvesting blood cultures:KCI (0.057M) warmed to 37'C in a water bath; allow 5ml ofKCI per tube.

.;'

'!•
'

Acetic acid (4%) at room temperature; allow Sml per tube.
Fixative (3 parts methanol to I part acetic acid) prepared fresh; allow 5ml/wash.

Procedure:
Working in a biohazard hood, the blood culture was transferred to a centrifuge tube

i

-'\

..l
..

(!Om!) and the cap was screwed on tightly. The tubes were then centrifuged at 1500

.]
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rpm for 5 minutes, the supernatant was removed and the pellet of lymphocytes

I

resuspended. A hypotonic solution was added to the tube (5ml of KCl per tube at
37"C) and mixed, the tube was then centrifuged at 1500 rpm for 5 minutes to lyse the
erythrocytes. The tube was carefully removed from the centrifuge, the supernatant
above the buflY coat removed and the pellet resuspended. Acetic acid (5ml of 4%)
was added to the tube with mixing and the tubes centrifuged at 1500 rpm for 5

minutes. All but 0.5ml of supernatant was removed and the pellet was resuspended
in the excess supernatant. The pellet was washed in Sml of fresh fixative ensuring
that the tube was well mixed, then centrifuged at 1500 rpm for 5 minutes. The
supernatant was then carefully removed without disturbing the pellet. A further 5

minute wash in fixative followed this step and the tube was centrifuged as before.
The supernatant was removed from the tube (with approximately 0.2ml left in the
tube) and the pellet resuspended. The cell suspension was then ready to drop as

metaphase spreads.

lii.3 .iy). Droppin& and fixation on to mjcroscape sljdes of cell preparation
With a thin tipped lml disposable pipette, fresh fixative was added to the cell

suspension drop by drop until the suspension cleared to a very faintly opaque
consistency. A microscope slide was placed flat on the bench top and, using a fresh

'i

'
I
.j
.,

I

pipette, from a height of approximately 20cm I drop of cell suspension was dropped
on to the slide. (All microscope slides were pre-cleaned by soaking in methanol for

I

'

I

I

l
l'

..
-:'

at least 30 minutes and allowed to air dry under a dust cover). Just before the drop
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dried it wa" covered with a drop of fresh fixative and allowed to dry before the slide
was moved, (as the drop of methanol/acetic acid fix spread across the slide the sides
were carefully wiped with a tissue to prevent any back-flow of fix interfering with
chromosome fixation).

IILJ.v). Examination by phase contrast microscopy
When the slide was dry it was examined by phase contrast microscopy. Metaphase
chromosomes should be clearly visible. Chromosomes were judged to be well
spread when there were at least 20-30 clear metaphases viewed under the
microscope.

Good preparations should be dark grey in colour with a minimal

amount of cytoplasm visible; if the chromosomes were pale it was a sign that they
were too dry and ifthey were shiny and black they were said to be refractile. Both of
these variant fonns would be detrimental for in situ hybridisation or Giemsa banding.
To prevent chromosomes from being too dry they were dropped onto a microscope
slide which was placed on top of a paper towel that had been pre-warmed by soaking
.,'

in hot water. Refractile chromosome preparations could be dropped in a fume hood

i'

next to a lighted Bunsen burner in order to optimise their banding potential.

III.3.vi).

Stora~e

of slides and suwius suspension.

If the slides were not immediately required for dropping, the tubes containing the
harvested cell suspension were filled to the brim with fresh fixative and stored at 4 'C
for up to 3 months. Alternatively, only 5ml of fresh fixative was added and they

'

'
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were stored at -20°C for up to I year. After storage the tubes were twice centrifuged

as before and the supernatant removed, the pellet was then washed both times in 5ml
of fresh fix before dropping.

!11.4. In situ hybridisation

II1.4.i). Protocols for in situ hybridisation
A number of different protocols were used in order to produce a suitable method for
in situ hybridisation wHch would be successful with the C179 probe. The protocols

were modified for the various labelling techniques that were carried out. In the
following pages these protocols are outlined and the specific variations made to each
for C179 cosmid probe in situ hybridisation will be expanded upon in the Discussion
section of the thesis.
lll.4.i).a. Prow col #I direct method
The first attempt at in situ hybridisation was using C!79 which had been labelled

directly with Fluorogreen® (Amersham).

It is a modification of the in situ

hybridisation protocol from the Department of Cytogenetics and Molecular Genetics
at Adelaide Women's and Children's Hospital and the protocol supplied with the

fluorochrome by Amersham.
DAY!:
''

_j

!. A Coplin jar (with lid) containing SOml of 70'/o deionised formamide/2xSSC (pH

7.0) was left to heat in a water bath set at 70°C.

,,l

J

'l

)'
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2. RNase A

(200~1

of O.lmg/ml) was pipetted on to each slide covered with a glass

coverslip (22 x 50mm). The slides were incubated for I hour at 3 7°C in a sealed

plastic container with a 2xSSC saturated environment.
3. At the end of the hour, the coverslips were removed from the slides and the slides
washed as follows:

The slides were washed for 4 x 1 minute in 2xSSC at room temperature with
agitation, using fresh 2xSSC each wash. The slides were dehydrated through a series

of alcohols (70% ethanol, 95% ethanol) for 1 minute in each, then rinsed quickly in
1-2ml of 100% ethanol. The slides were then stood upright and allowed to dry at

room temperature. When dry they could remain at this stage for several hours.
4. In order to hybridise probe DNA to chromosomal DNA both were denatured so
that they were single-stranded. The probe DNA was denatured first, with lOOng of
probe DNA used per slide. Cl79 with Fluorogreen had a concentration of IOOng/~1,
therefore

1~1

of Cl79 per slide was pipetted into a small (600,.U capacity) microfuge

tube along with driver DNA. The driver DNA used in this instance was autoclaved
salmon sperm DNA; a ratio of75:1 driver:cosmid DNA was used. The driver DNA
and the probe DNA were then desiccated to zero volume in a "speedivac". (It should

be noted that fluorescein is light-sensitive and as such should be exposed to only the
minimal amount of light). When this reduction in volume had been achieved I 0~1
per slide of Kevil's hybridisation mix was added to the tube. The tube was quickly
vortexed and then centrifuged at 12000g for~ 20 seconds in a microfuge. The DNA

was then be denatured by heating for 5 minutes in a thermal cycler, (various

'i
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temperatures, 70°C or 94°C, were tested using this method). The tube was removed
from the machine at the end of the cycle and placed immediately on ice for 1 minute.

The probe was then allowed to pre-reassociate for 30 minutes at 37°C.

The

chromosomal DNA on the slides was then denatured to correspond to the completion
of the 30 minute incubation period. To denature the slides they were placed for 3
minutes in the 70% fonnamide/2xSSC which had been pre-warmed to 70°C. V.'hile

slides were in the Coplin jar the tube was vortexed and quickly centrifuged at
12000g for r::: 20 seconds in a microfuge. The slides were removed from the Coplin
jar and, without allowing them to dry, lOft] of the tube contents was applied to the

centre of each slide. The slides were then covered immediately with a 22 x 22mm
glass coverslip which was secured with a spot of clear nail varnish. The slides were
put into a sealed plastic container with a 2xSSC saturated atmosphere and hybridised
overnight (16 hours) at 37°C.

DAY2:
I. Two Coplin jars containing 50ml aliquots of 50% formamide/2xSSC were heated

in a waterbath to 42°C. When this temperature was attained, the sealed container
with slides in it was removed from the incubator. The slides were taken out of the
container and the coverslips removed. The spot of nail varnish which secured the
coverslips should also slide off, if it did not the edge of a scalpel blade was used to
chip the varnish off the slide and the coverslip then removed.

2. After the coverslips had been removed the slides were washed 'With agitation as
follows:
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Twice for I0 minutes in 50% formamide/2xSSC at 42°C, twice for 5 minutes in
2xSSC at room temperature and once for 5 minutes in IxSSC at room temperature.
3. The slides were then rinsed twice for 2 minutes in PBS at room temperature and
drained briefly but not allowed to dry.

4. The chromosomes were counter-stained with the application of 20~ of anti-fade
solution with propidium iodide to each slide.
5. The slide was then covered with a 22 x 50nun coverslip, and at this stage the slide

was ready to view under a fluorescent microscope at the appropriate wavelength.
NB slides were kept in the dark at 4°C, as colour of signal fades significantly within

48 hours if exposed at room temperature.

lll.4.i).b. Protocol# 2 in situ hybridjsation ofCI79labelled with Biotin-16-dUIP
This labelled probe was received from the Department of Cytogenetics and

Molecular Genetics at the Adelaide Women's and Children's Hospital. The protocol
used was the one supplied by that Department.
DAY I:
I. Steps 1-3 from day I protocol #I were repeated.

2. Again the probe DNA was denatured prior to the denaturation of chromosomal
DNA. The optimal ratio of driver:probe DNA was determined by the Adelaide
laboratory to be 400:1. To accomplish this ratio 20ng of probe and 8000ng of driver
COT-I DNA (COT-I) per slide were pipetted into a small microfuge tube and co-

desiccated to zero volume in a "speedivac, as before.
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3. Kevil's hybridisation mixture (IOf!Vsiide) was added to the tube, which was then
vortexed and quickly spun in a microfuge as in step 4 protocol #I (DAY!).
4. The tube contents were denatured by placing the tube in a polystyrene foam

surround and floating it in a water bath at 70°C for 5 minutes.

It was then

immediately placed on ice for 1 minute, after which time the tube was incubated at
37'C for 40-90 minutes. The chromosomal DNA was denatured on the slides in
70% formamide/2xSSC as in step 4 protocol #! (DAY I) and IOfll of denatured
probe was applied to each slide and covered as before.

The slides were again

hybridised overnight at 37'C in a 2xSSC saturated atmosphere.
DAY2:

1. The slides were removed from the sealed container and steps

1~2

from protocol #l

(DAY 2) were repeated.

2. This probe was labelled with biotin and it was therefore necessary to incubate the
slides with an antibody conjugated to fluorescein or an enzyme to detect

hybridisation signal in this protocol.

In this case streptavidin-FITC was used;

streptavidin has a high binding affinity to biotin and it was conjugated to fluorescein.
3. Before the streptavidin-FITC was added, the slides were first treated at room
temperature as follows:
The slides were rinsed for 3 minutes in 4xSSC/0.05% Tween 20® in a Coplin jar at
room temperature. The slides were pre-incubated in 4xSSC/I% BSA (IOOfll per
slide under lab film) for 10 minutes (2xSSC saturated atmosphere).
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4. The slides were kept in the dark as soon as the fluorescein conjugate was applied
and they were not allowed to dry out. Drying was prevented by keeping slides in a
2xSSC saturated atmosphere during incubation periods. The streptavidin-FITC was
made up to a dilution of I :250 in PBS, 60f1l per slide (under lab film) was applied to

each slide, and the slides incubated at room temperature for 20 minutes.
5. The slides were washed and rinsed as follows:
00

Twice for 5 minutes in 4xS5C/0.05%Tween 20 (lOOfll per slide under lab fihn),

then once for 2 minutes in 2xSSC and finally twice for 2 minutes in PBS.
6. The slides were then counter-stained and covered with coverslips as in steps 4 &
5, protocol# I (DAY 2).

lll.4.i).c. Protocol# 3 in situ hybridisation

of C179 labelled with Di2oxjj:enjn-ll-

A number of detection methods were attempted with the Cl79 probe that was
labelled with digoxigenin (DIG). These include fluorescent in situ hybridisation
(FISH) using an antibody conjugated to FITC, and non-isotopic in situ hybridisation
without the use of fluorescence. The first part of the protocol. for both types of

detection was the same.
DAY!:

I. Steps 2-3 from day I protocol #I were repeated to RNase slides and the slides

rinsed.
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2. COT-I driver DNA and probe DNA were pi petted into a small microfuge tube and

co-desiccated as before to zero volume. A number of driver:probe ratios were tried,
they ranged from 16:1 to 500:1.
3. Kevil's hybridisation mixture(! 0111 of per slide) was added to the tube and the tube
was then quickly vortexed and centrifuged as before.

4. The tube contents were denatured by floating it in a 70°C waterbath for 5 minutes,

it was then placed on ice for 1 minute to ensure that the DNA remained singlestranded.
5. The probe DNA pre-reassociated by leaving it to stand at 37'C for I 0-90 minutes.

6. At the end of this time the tube was vortexed and centrifuged as before and I 0111
of probe mixture was applied to each slide.
7. The mixture was covered with a 22 x 22mm glass coverslip and all the edges of

the coverslip and slide were sealed with rubber cement.
8. The rubber cement was allowed to dry for 5-15 minutes, and the chromosomal
DNA was then denatured by heating the slide on the upper surface of a metal plate in
a waterbath at 70-75'C for 10 minutes. (The metal plate was positioned on the

surface of the water and prevented the slide from becoming immersed).
9. The slide was removed from the waterbath and incubated overnight at 37°C in a
2xSSC saturated environment.
DAY2:
J• Rubber cement was

removed from around the coverslip with forceps and the cover

slip was then allowed to slide off the slide as it was washed.
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2. Slides were washed at 37°C with agitation as follows:

Twice for 6 minutes in 2xSSC, twice for 7 minutes in lxSSC and then once for 8
minutes in O.lxSSC.

3. After washes the detection method of choice was followed.

)IJ.4.i).c.(ll).

Anti-di~oxi2enin

horse radish peroxidase Q'OD) or (g.-DIG HRP)

detection

l. Each slide received 7.5 units of a-DIG HRP in TBS to a total volume of70Jll per
slide, (3.51!1 of a-DIG HRP in 66.51!1 of TBS). The slides were incohated in this

solution for 1 hour at 37°C, in a 2xSSC saturated environment.
2. The slides were then washed twice for 5 minutes in TBS.
3. To detect the horse radish peroxidase a colour solution was applied to the slides.

The colour solution was made from the following reagents; 6.0mg of diaminobenzidine solution (DAB), !Om! ofTBS and lOJll ofH2 0 2 (30%). It was mixed and
then filtered through a sheet of fluted filter paper on to the slides. The solution was

never prepared in advance because it is extremely heat and light sensitive, any

surplus was discarded. The colour solution was left on the slides for I0 minutes and
then removed by three I minute washes with agitation in TBS at room temperature.
4. The slides were most often counter-stained in 3% Giemsa solution for:- 10-15
minutes. Alternatively, haematoxylin followed by Scott's tap water was used as a
counterstain (see ll.2. Reagents in use).
).
•
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5. Each slide was air-dried and mounted in DePeX mounting

~:._,edia,

then covered

with a glass 22 x 50mm coverslip. When the mounting media was dry slides were
viewed under a light microscope.
Ill.4.i).c.!b).

Anti-di~oxigenin

fluorescein (lx-D!G FITC)

I. After tbe slides had been washed as in step 3 (DAY 2) tbey were rinsed for 3

minutes in 4xSSC/0.05%Tween 20® in a Coplin jar at room temperature. The slides
were then pre-incubated (in a 2xSSC saturated atmosphere) for 10 minutes in
4xSSC/l% BSA (I 00~1 per slide under lab film).

I

I
I

I

2. The slides were kept in tbe dark from this step on. The antibody used for
detection, a-DIG FITC, was made up to a dilution of I :250 in PBS and applied to
the slides

(60~1

per slide under lab film), tbey were tben incubated for 20 minutes in

a 2xSSC atmosphere at room temperature.
3. The slides were washed and rinsed as follows:
Twice washed with agitation for 5 minutes in 4xSSC/0.05%Tween 20® (100~1 per

slide under lab film), then rinsed once in 2xSSC for 2 minutes and twice in PBS for 2

minutes.
4. The slides were counter-stained and coverslips applied as in steps 4 & 5, protocol
#I (DAY2).

IIL4,i),d, In situ hybridisation ofOocor probe labelled with DIG-11-dUTP

This probe was hybridised in acrordance with manufacturer's recommendations.
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DAY!:
I. The slides were pre-treated in 2xSSC for 30 minutes at 37'C. The slides were
then dehydrated through a series of ethanols (70%, 80%, Md 100%) at room

temperature for 2 minutes each, after which they were stood upright and allowed to
dry.
2. The slides were denatured in 70% formamide/2xSSC at 70'C for 2 minutes then
dehydrated through a series of ethanols (70%, 80%, and 100%) at -20'C for 2

minutes each. Again the slides were stood upright and allowed to dry.
3. The probe was pre-wanned at 37°C for 5 minutes, it was imperative that this probe
was not heat denatured.
4. The oro be which was mixed with a hybridisation solution prior to purchase, was
applied (I O;tl to each slide) and covered with a 22 x 22mm glass coverslip which

was tht:n sealed with rubber cement.
5. The slides were hybridised overnight (16 hours), in a humidified chamber at 37'C.

DAY2:
I. The slides were washed in 50% formamide/2xSSC (pH 7.0) at 43'C for
IS minutes, followed by an 8 minute wash in 2xSSC at 37'C. The slides were then

transferred to PBS at room temperature where detection could proceed.
2. Full strength anti-digoxigenin FITC was applied to slides (60~1 per slide) and
they were incubated in a dark humidified chamber at 37'C for 5-30 minutes.

3. Slides were then rinsed three times for 1 minute in PBS at room temperature.
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4. The chromosomes were

counter~stained

in antifade mounting medium with

propidium iodide, at a final concentration of0.3 fig/mi.

III.4.ii). Amplification steps for in situ hybrjdjsatjon
AII of the hybridisation protocols #2-4 can make use of amplification steps in order
to amplify hybridisation signal. Instead of just one antibody being used, 2 or more
steps were carried out. For example, rather than using just anti-digoxjgenin horse
radish peroxidase for a 1-step detection, anti-digoxigenin fluorescein fall owed by
anti-fluorescein horseradish peroxidase could be used. This amplification step can
increase the intensity ofhybridisation signal.

lll.4.iii). Enhancement ofDAB
Hybridisation signal detected by the DAB colour reaction can also be intensified by
the use of metals. At the end of the colour reaction and before washing in TBS,
slides were rinsed in 2% CuS04(aq) at room temperature for 2 minutes.
increased the precipitation signal of DAB.

This
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111.5. MjcrosCOIIY

III.5.i). Fluorescent microscope for fluQrescejn/PI

To view slides counterstained with propidium iodide a Leitz fluorescent microscope
was used at a wavelength of 595nm, this wavelength allowed the simultaneous

visualisation of both propidium iodide and fluorescein-12-dUTP.

III.5.ii). Confocal scannini: microscupe
Slides which were stained by fluorescent reagents could be viewed under a confocal
scanning microscope.

This microscope was more sensitive than a standard

fluorescent one and it can therefore detect hybridisation signal with greater clarity.

The microscope used was at the Electron Microscopy Centre at the University of

Western Australia and was operated by Dr. Ulrich Seydel.

III.S.iij).

Li~hl microscope

for HRPIDAB/Giemsa

Slides counter-stained with Giemsa were viewed under a Leitz light microscope at

high power with oil immersion.

II1,5,iy). Geneyjsion used to produce jmar.:es ofli2ht microscqpe slides

A light microscope at the Cytogenetics Department of SHLS (WA) is connected via
a video camera to a software package called "Genevision". This package allowed
images from microscope slides at high power to be transferred on to a computer

72

screen so that karyotyping could be done.

Print outs from "Genevision" of

hybridised metaphase spreads are shown in the results section.

73

IV. Results
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IV. Results

IV.l. Isolation ofC!79 [rom bacteria

IV.l.D. Isolation of CI79 DNA from bacteria and determination ofthe size
As previously stated (p44), cosmid CI79 arrived from the U.K. as an agar stab
culture, since no information was provided on the species or strain ofthe bacterium it
was treated as Escherichia coli (E. coli) one of the more common types of bacteria
used for plasmid and cosmid transfection. The Mini-preparation of C179 produced a
visible pellet of DNA and the cosmid DNA thus isolated by this method was run on a
mini-gel against markers of known size. It was determined that the DNA isolated
was around 40kb in size when compared to markers of known molecular weight.

IV.l.jj). Maxi-pre])aration of cosmid Cl 79
After C179 was successfully isolated from a small scale preparation, a maxipreparation was set up. The maxi-preparation yielded 16 Eppendorf tubes of DNA at
various w/v concentrations. Half of the tubes were sent to the Department of
Cytogenetics and Molecular Genetics at Adelaide Women's and Children's Hospital,
the remainder were rdained trJ be labelled and used in in situ hybridisation reactions.
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IV.2. Probe labelline

IV.2.D. Concentration ofcosmjd DNA

In order to label the probe the DNA concentration must first be determined, this was
done by the absorbance method outlined in the Methods section. When a sample of
CI 79 was tested by this method the following results were obtained.

Table IV. 1 Concentration and purjty of cosmid DNA

DNA PURITY CHECK FACTOR 50

ABSORBANCE
RATIO MODE

260nm

wavelength

280nm

ref

O.OOOA

O.OOOA

celll

0.055A

0.030A

RATIO
concentration
at wavelength
260nm

1.831

= 2. 751!g/ml

After a 1 in 2000 dilution the isolated cosmid DNA had a concentration of
2.75JJ.g/ml; this figure was used in order to calculate the volume of DNA required for
labelling reactions.
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IY.2.ii).

Labellin~

of C I 79 with di~oxigenjn lzy the random primed method

A number of aliquots of DNA were labelled during the course of this research, and

all were first tested to determine DNA concentration and purity as described above.
The volume of DNA in solution which corresponded to lf1g was diluted to a final
volume of I Ofll in ddH20 for each labelling reaction.

Labelling of DNA with

digoxigenin was confirmed as previously described (p54), using a nylon membrane
with alkaline phosphatase to detect hybridisation. Figure IV.! shows an example of

one such membrane. The dots represent two areas of hybridisation with the labelled
cosmid DNA, they appeared after 10 minutes incubation and the reaction was
stopped after 40 minutes (the signal remained visible on the membrane for a further 4
months).

IV.2.iji). Confinnation that the isolated probe was C179
In addition to the request for information ac; to the nature of the bacterium supplied,
the Newcastle (U.K.) group were also asked to provide a cosmid map and restriction
digest information. To ensure that the DNA isolated was cosmid CI79 (and did not

result from contamination with another cosmid or piasmid), a restriction digest of the
cosmid was performed with 3 of the more common restriction enzymes, Bam HI,
Eco Rl, and Hind III. The resulting

mini~gel

which consists of lanes

1~8

running

from left to right is produced in figure IV.2. It shows that the uncut Cl79 in lane 3

has three bands representing the three possible forms of DNA, these are:~
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(i) Double stranded circular DNA which has only one of the strands nicked, i.e., it
travels slowly through the gel as a large circle of DNA.
(ii) Double stranded circular DNA which has both strands nicked and moves through
the gel more quickly as a linear strand of DNA.
(iii) Double stranded circular DNA that has not been nicked, this form of DNA tends

to constrict into a spherical form and migrates through agarose gels faster than either
of the nicked DNA forms.
Lanes 4-6 show the restriction digest of Cl79 with Bam HI, Eco RI & Hind III
respectively. Lane 8 contains a DNA marker (1.-Pst 1) of known size. The results of

a similar experiment were recently received from the U.K. and are shown in figure
IV .3 as a southern blot of C 179 digested by Hind Ill. Although this digest cannot be

directly compared to those shown in figure IV.2. the size of the bands which result
from the Cl79 Hind Ill lane were of equivalent size when compared to!V.3. The
photograph (IV.3) was supplied by the laboratory which donated the probe, The
Department of Human Genetics at the University of Newcastle Upon Tyne (UK}

•
!
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Figure IV. 1:
Membrane to check labelling of Cl79 probe with digoxigenin, dots represent areas
ofhybridisation with labelled probe.
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Figure IV.2:
Restriction digest of C 179 cut with the restriction enzymes, Bam HI, Eco RI and
Hind III. Gel lanes are loaded as follows:

LANE CONTENTS & NUMBER
nil

nil

uncut

C179 · ;··C179
with ' ·.with '

1

2

3

Bam HI

Eco RI

4

5

Cl79

nil

A.-Pst 1

7

8

with
Hind ill

6
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IV.3:

Southern blot from the U.K. of C 179 digested with Hind III as marked.
ltBtW(;fJ'JftL!

i "

.... r:
I

~

:

.'' .
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IV.3. Preparation of metaphase chromosome spreads

IV.3.i).

Cbromo~·ome

spread production and quality

Metaphase chromosome spreads were processed at the Cytogenetics Department of

SfiLS. Although there was insufficient time during this project to perform in situ
hybridisation on all of them, over 100 specimens were cultured and processed. All
specimens have been karyotyped from synchronised cultures, and many high

resolution karyotypes have also been performed by this department. The specimens
set up yielded high quality metaphase chromosomes which banded successfully.

IV.3.ii). Results ofcyto~enetjc karyotyping of DGS patients
As was expected, few of the suspected DGS patients showed a microdeletion of

chromosome 22qll cytogenetically (Carey et

a/., 1992), however to date two

patients in the sturfy show monosomy 22q 11 from high resolution studies.

The

resulting metapha•,e spread and karyotype of the synchronised culture and the

metaphase spread and ideogram of the high resolution culture is shown from one of
these patients in figures IV.4-IV.7. No apparent aberration is observed from the

synchronised culture but monosomy 22qll is detected on the high resolution slide
(see figures IV.6, arrows indicate both 22 chromosomes and Figure IV.7 which
shows a partial karyotype of the chromosomes). The work on these karyotypes was
performed by the Cytogenetics Department at SHLS.
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Fi2ure IV.3:
Metaphase spread of synchronised peripheral whole blood culture.

/
...
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Figure IV.5:
Karyotype of synchronised peripheral whole blood culture, shown in figure IV.4.
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Figure IV.6:
Metaphase spread of high resolution (HRS) peripheral whole blood culture.

10/24/94 30604.ME1
46,XY,delC22)Cq11.2)

30604 LS BL KH HR2 99.

.

'

.
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Figure IV.7:
High resolution partial karyotype of patient displaying monosomy 22q 11, with
accompanying ideogram of chromosome 22.
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!V.4. In situ bybridisation

IY.4.Q.- In siftl bybridisation with Fluorocreen labelling
All attempts at hybridisation using this method failed to show hybridisation signal.

The metaphase chromosomes stained well with propidium iodide and were clearly
visible under the fluorescent microscope at A = 595nm.

There also was no

background signal detected by this method. Fluorogreen from the same batch had
been used to label a probe by this method at the Department of Haemotology at__
Royal Perth Hospital, but this probe labelling was also unsuccessful.

It was

determined therefore that this method would not be pursued further, both because no

new Fluorogreen was available and the random primed method with digoxigenin
labelling was proving to be reliable.

lV.4.ii). In situ hybridisation with bjotjn labelling
As previously noted, a sample ofC179 was sent to the Department of Cytogenetics
and Molecular Biology at the Adelaide Women's and Children's Hospital. This

sample was sent to the laboratory primarily to verify that the cosmid isolated in Perth
was Cl79, and that it did in fact hybridise to chromosome 22qll. The reason for the

choice of this particular laboratory was it's past success in using a cosmid probe for
chromosome 22qll donated by the Newcastle group (U.K.), and it also has several
years experience of in situ hybridisation.

In Adelaide it was confirmed by

.fluorescent in situ hybridisation (FISH) that C 179 cosmid hybridised to chromosome

i
K-
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22q 11. This confirmation, and the results of the restriction digest and southern blot,
suggest that the correct cosmid was isolated by maxi-preparation. A sample of
biotinylated Cl79 probe was returned from Adelaide for use in the present study.
Several attempts were made to undertake FISH with this probe using a sightly
modified version of the Adelaide protocol, however none of the metaphase

chromosome spreads showed hybridisation signal, although fluorescent background
signal was apparent on many of the slides.

IV.4.iii). In sUu hybridisation with djgoxigeojn Jabellinfi

IV.4.iii).a. Horse radish peroxidase and DAB conjugated to DIG
Due to a lack of success with FISH using Cl79 labelled with Fluorogreen and biotin,
an alternative label and detection system was investigated. The C179 probe was
labelled with digoxigenin by the random primed method and tested for correct

labelling. When it was confinned that this probe was labelled with digoxigenin, in
situ hybridisation was undertaken. Horse radish peroxidase was used instead of

fluorescein to detect the reporter molecule, and hybridisation signal was then
visualised with diaminobenzidine (DAB). Several hybridisation experiments using
this method resulted in apparent hybridisation of Cl79 to a G-group chromosome,
presumably chromosome 22. A summary of some of these results are outlined in
table IV.2 which is accompanied by figures IV.8-IV.20. Double arrows indicate
regions of apparent hybridisation on G-group chromosomes, and single arrows point
to the other G-group chromosomes where no signal is visible. There are no arrows
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on metaphase spreads which show excessive non-specific signal. Unless indicated,
patients all display phenotypes consistent with DGS.
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Table IV.2. Summar; ofjn situ hybridjsation results

PatientiD

fig#

Hybridisation

I~

34924MAP

8
1

36153MTC

9

36154MRO

10

35181M LS

36019MNP

on 1 0-chromosome
marked by double arrow

Signal was strong
some background visible

'V on 1 G-chromosome
marked by double arrow

Signal visible under
microscope -dark on print

IV

Poor chromosome
morphology

I~

Mother of patient in figs
IV.4-JV.7;
only subtle signs ofDGS
Signal and chromosomes
pale

on 1 G-chromosome
marked by double arrow

on 1 G-chromosome
marked by double arrow

11

12

I -v

on 2 G-chromosomes
marked by double arrows

I~

on 2 G-chromosomes
marked by double arrows

Chromosomes pale

on 2 G-chromosomes
marked by double arrows

Morphology of
chromosomes poor

-v

on 2 G-chromosomes
marked by double arrows

Signal and chromosomes
pale

I~

16

on 2 G-chromosomes
marked by double arrows

Signal and chromosomes
pale

17

on 2 G-chromosomes
marked by double arrows

Signal was visible under
microscope -dark on print
Chromosomes dark

35976M SC

13

36055MJH

14

'i

I

35990MAB

44444M
(control)

15

'I

36159MAA

Comments

but signal present

35945MCA

18

on 2 G-chromosomes
marked by double arrows

36225MJP

19

No signal visible

4X nonnal strength DAB

Excessive signal on all
chromosomes

Impossible to comment on
G-group chromosomes

'i

35506M NT

20

but signal present
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IV.8:

Metaphase spread of patient 34924M AP, shows hybridisation signal detected with
the use of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome
(marked with double arrows).
09/30/9~

34924M.ME1

34924M AP BL MM 4 103.2 4
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Figure IV.9:
Metaphase spread of patient 36153M TC, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with
double arrows). Counter-staining is dark, but signal was visible when viewed under
the microscope.

09/30/94 36153M.ME1

36153M TC BL MM 1 fil

..
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Figure IV.lO:
Metaphase spread of patient 36154M RO, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with
double arrows).

Counter-staining is dark and chromosome morphology is poor,

however signal is clearly visible.

09/30/94 36154M.ME2 36154M RO BL MM 1 fil sav

.·

. '.

93

Figure IV .11 :
Metaphase spread of patient 35181 M LS, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 1 G-group chromosome (marked with
double arrows). This culture was prepared from the mother of patient 30604 LS,
who was shown to have monosomy 22q 11 by HRS karyotyping.

09/30/94 35181M.ME3

35181 LS BL MM fil sav

.

. .
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Figure IV.l2:
Metaphase spread of patient 36019M NP, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows).

Hybridisation signal and chromosomes were pale due to

shorter exposure time to counter-stain.

09/30/94 36019M.ME2 36019M NP 8[ MM 1 fil sav

•

c •

'
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IV.13:

Metaphase spread of patient 35976M SC, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows).

Hybridisation signal and chromosomes were pale due to

shorter exposure time to counter-stain.

35976M.ME4 35976M SC BL MM 3 96.3 45.0

..

•
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Figure IV.14:
Metaphase spread of patient 36055M IH, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows).

Hybridisation signal and chromosomes were pale and

chromosome morphology was poor, tllis was probably caused by washing slides with
too high a stringency.

09/30/94 36055M.KA1 36055M IH BL MM 103.9 44.

•

< •
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Figure IV.15:
Metaphase spread of patient 35990M AB, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows). Hybridisation signal was pale but visible when viewed under
the light microscope; hybridisation signal was also detected on 2 chromosomes from
this patient with the confocal microscope.

09/30/94 35990M . ME1 35990M AB BL MM 1 109 . 0 48 . 3
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Figure IV.16:
Metaphase spread of control patient 44444M, hybridisation signal detected with the
use of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows). Non-specific hybridisation signal was also seen on some
chromosomes, this can be reduced by increasing stringency of washes and by
altering probe:driver ratio
~9/30/94

44444M.ME1

44444M CONTROL BL MM 100.9 44.

•

•

•

.·

- . ..
-~
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Figure IV.17:
Metaphase spread of patient 36159M AA, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double arrows). Hybridisation signal is distinctly visible on both chromatids of
the two chromosomes marked.

09/ 30/ 94 36159M . ME2 36159M AA BL MM 104.4 42 . 7

•

l
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Figure IV.18:
Metaphase spread of patient 35945M CA, hybridisation signal detected with the use
of anti-DIG HRP and visualised with DAB, on 2 G-group chromosomes (marked
with double anows). Hybridisation signal is dark on both chromosomes.

19/30/94 35945M .MEl

35945M CA BL MM fil sav

•

'

,.

.
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Figure IV.19:
Metaphase spread of patient 36225M JP, no hybridisation signal was detected on the
chromosomes. The strength of DAB was increased in order to increase hybridisation
signal intensity, however this change darkened all chromosomes and distorted their
morphology.

09/30/94 36225M.ME2 36225M JP BL MM 1 fil sav
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Figure IV.20:
Metaphase spread of patient 35506M NT, a high degree of non-specific hybridisation
signal was detected on all chromosomes.

This amount of signal was due to a

reduction in the driver:probe ratio and means that any signal detected on the G-group
chromosomes is meaningless.

35506M NT BL MM 3 fil

09/30/94 35506M.ME1

•

•
•

..

sa~
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IV.4.iii).b. Fluorescein conjugated to DIG.
Fluorescent in situ hybridisation was also performed on Cl79 labelled with

digoxigenin.

No hybridisation signal was detected using either 1- or 2-step

amplification methods by fluorescent microscopy, however a signal was apparent on
one metaphase when scaoned by a confocal microscope (see figure IV.21). Other

metaphase spreads with obvious background signal present when viewed by this
method revealed large amounts of cytoplasm covering chromosomes (see figures

IV.22-IV.25).

It can be presumed that excessive cytoplasm prevents the

hybridisation of probe DNA to chromosomal DNA by acting as a physical barrier.
Signal was also detected from interphase nuclei by this method (see figure IV.26),

although it was not determined if this was hybridisation signal or background signal.
All hybridisation and background signals on figures IV.21-IV.26 are indicated by
arrows.
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Figure IV.21 and IV. 22:
IV .21. Shows metaphase spread with apparent signal on 2 chromosomes.

IV.22. Non-specific signal shown.
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FifWre IV.23 and IV. 24:
IV.23. Shows metaphase spread with surrounding background signal.

IV.24. Bright backgound signal shown.
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Figure IV.25 and IV. 26:
IV .25. Shows metaphase spread and surrounding interphase nuclei with signal.

IV.26. Backgound signal outside interphase nuclei with pale signal inside 1 nucleus.
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IY.4.iv). In situ bybridisation with D22S75 Oncor pro~
D22S75 was purchased from Oncor, with sufficient probe supplied to hybridise 20
slides. Using this probe fluorescent in situ hybridisation was carried out on three
slides but since a hybridisation signal was not detected on any of these slides, and

due to the expense of the cosmid probe (over $30 for each slide), it was decided that

a more detailed protocol probably was required.

..

After discussion with the

manufacturer, two Australian research groups who have used this probe have agreed
to supply their successful modified protocols, and on receipt of these protocols

sufficient probe remains to process a further 17 slides.

!I
;
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Y. Discussion
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V. Djscussjon

V.I. Introductjon

The detection of genetic disorders by the use of in situ hybridisation has been shown
by numerous researchers to be a most effective method to confirm clinical diagnoses
(Carey eta/., 1992). Although initially this technique has proved difficult to execute,
once the requisite experimental conditions are optimised routine diagnosis is
possible. Individual probes appear to have distinct optimal conditions for in situ

hybridisation which further comr :~cates establislunent of the technique. This is
particularly the case for wrique sequence probes, such as those used in the present
study, which require highly specific experimental conditions in order to visualise

signal without an excessive amount of non-specific signal.

In the following

discussion, aspects of in situ hybridisation which are necessary to successfully
expedite its use will be addressed.

V.2. Probe pre.paration
V.2.i). The preparation of an agar stab culture

Plasmids are small circular molecules of double-stranded DNA that occur naturally
in both bacteria and yeast; they replicate as independent units as the host cell
proliferates, This self-replication is exploited in molecular cloning (Alberts et a/.,

1983). Cosmids in their simplest form are modified plasmids that carry a copy of the
DNA (cos) sequences required for packaging DNA into bacteriophage A. particles.
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Cosmids carry an origin of replication and drug resistance markers so they can be

introduced into bacterial vectors by standard transformation procedures and
propagated as plasmids (Sambrook et a/., 1989, p. 3.5). The DGCR probe used in
this study is a cosmid probe (Cl79), and it has an insert of DNA which is

complementary to part of the DGCR. In order to clone this insert sequence the
cosmid was transfected into a bacterial vector in which it could replicate. Cosmid
probe C179 was received in a kanamycin~resistant bacterium as an agar stab culture
from Professor J Bums group in the UK. In addition to this probe, similar cosmid
probes from the U.K. group have been isolated from chromosome 22 libraries and

digested with the restriction enzyme Hind III, with fragments then shotgunned into a
Hind III digested vector to form cosmids (Wadey et a/., 1993). A photograph of
Cl79 cut with Hind III was received from Bums eta/, (figure V.3). In order to label
the cosmid for in situ hybridisation it must first be amplified and then isolated from
the bacterial host.

Y.2,ii). Yield ofcosmid DNA
Experimental conditions effect both the yield and purity of cosmid DNA prepared by
alkaline lysis (Sambrook et a/., 1989, p 1.25). To ensure a high yield of DNA,
special care must be taken to remove all supernatant from the bacterial pellet and
nucleic acid precipitate phases.

Attention should also be paid to the particular

temperature required at different stages of the reaction, e.g., if nucleic acids are
centrifuged at 4 °C instead of room temperature, the sodium salt present in solution

't
"

''
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may precipitate and become pelleted, thus causing contamination of the resultant
DNA (Sambrook eta/., 1989, p 1.39).

V.2.iii). The concentratjon of the isolated ffi.J"A

The concentration (w/v) of the isolated DNA must be measured so that a known
quantity of DNA can be labelled for in situ hybridisation. The concentration of DNA
measured using the absorbence method will highlight experimental contaminants
such as salts by yielding an abnonnal value. This method will not indicate the

presence of contaminant DNA or the isolation of the incorrect cosmid, because it is
unable to distinguish between different forms of DNA, or protein. For this reason it
was necessary to perform a restriction digest on isolated C179, the results of which

can be compared to the restriction digest of a pure sample of the probe. This method
allows confirmation that the correct cosmid was isolated and jodicates its level of
purity. If contaminant DNA is present, the restriction digest banding pattern will
differ from that given by the pure probe.

If this digest is not undertaken and

contaminant DNA is labelled, hybridisation signals can occur on unexpected
chromosomes giving confusing results and high levels of non-specific hybridisation.

V.3. Probe labelling
When it was confirmed that Cl79 had been isolated, probe labelling was carried out
using three different methods. These are sununarised below:

''

''

'

1,-
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Y.3.i). Direct labellin2
This probe labelling technique was attempted with FluorogreenTM (Amersham) a
fluorescein-12-dUTP conjugate which can be attached directly on to either a plasmid,
cosmid or YAC probe, by nick translation. The FISH carried out with directly
labelled C 179 was unsuccessful, with no hybridisation or background signal
detected. The absence of signal could be due to a number of reasons, including

failure of the nick translation reaction to incorporate fluorescent nucleotide into the
probe. However, without checking the probe labelling it cannot be assumed that
Fluorogreen was conjugated to C179. If labelling of the probe was achieved and
hybridisation did occur, it still may be difficult to detect signal. Directly labelled

probes require no amplification steps to detect hybridisation signal in FISH, and this

lack of amplification may be the reason why signal was not detected using probe
labelled by this method.

Y.3 .ii), Biotin labellin2
Biotin labelling of C 179 was carried out by the Adelaide research group using the
nick translation method. Probe labelling was not checked during the course of this

study because the biotinylated probe was used to successfully delineate chromosome
22q 11 in Adelaide by FISH. Although hybridisation signal was not visible when this

probe was used in Perth, background signal was detected on some metaphases. This
tends to suggest that the probe was labelled and that it was either a deficiency in
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hybridisation or detection of hybridisation during another stage in the FISH reaction
that prevented visualisation of the signal.

V.3.iii). DIG labelling
C 179 probe was labelled with digoxigenin-11-dUTP using the random primed
method. This form of labelling was confirmed by detecting the hybridised probe on
a nylon membrane with the enzyme alkaline phosphatase. Digoxigenin-11-dUTP
(DIG) labelling proved to be very successful and it was straightforward to perform
the labelling of the probe and to check this labelling. Hybridisation signal from ISH
experiments was detected in each of the several batches of probe labelled by this
method.

V.4. Slide preparation
Slide age and condition are among the numerous factors which effect the overall

quality of chromosome metaphase spreads. Only good quality slides are used at the
Cytogenetics Department at SHLS, each batch of slides is dated on arrival at the

laboratory and those which are not used within six months of receipt are discarded.
Even though the slides are clean when purchased, they are further cleaned by soaking

in methanol, which ensures that when the cell suspension is dropped on to the slide it
spreads evenly and is not affected by contaminant debris either on the slide or arising
from the cell preparation.

Excessive ammmts of cytoplasm can be a particular

problem encountered in the production of metaphase spreads, and many innovative
1

_.;

c!
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,echniques have been employed in order to reduce the amount of cytoplasm around
cells. The method which seemed most efficient in decreasing unwanted cytoplasm

was recommended by the Cytogenetics and Molecular Genetics Department at
Adelaide Women's and Children's Hospital (E. Baker, personal correspondence).

She suggested that, after cleaning, slides should be soaked in absolute ethanol at
room temperature and then dipped into luke warm distilled water before the cell

suspension is dropped on to the wet slides held at an angle of approximately 45° over
a water bath at 50°C, This technique proved most helpful when fixed cell suspension
had been stored at 4°C or -20°C for extended periods after harvesting of the cells.

Slides used for in situ hybridisation require different conditions prior to use to those
dropped for synchronised karyotyping with G-banding. Slides are not baked at 60'C

overnight to artificially age chromosomes, instead those dropped for in situ

hybridisation reactions are stored at room temperature, because baking slides can
decrease the hybridisation signal. It. has also been noted that slides which are stored
in dry conditions (in a desiccator) at room temperature produce a better hyhridisation
signal (Lisa Robson, Cytogenetics Dept. Carnperdown Children's Hospital NSW,
personal correspondence). Slides were usually employed in t.'>is study 1-5 days after

dropping, however in most instances it is recommended that slides be used within a
30 day period after dropping. If the cell suspension is not dropped immediately after

processing it can be stored at 4°C or -20°C. Unfortunately it was observed that
hybridisation may be hindered by increased amounts of cytoplasm surrounding tl10se

'

'r.·'

1'
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cells which have been stored in this way. Although there are techniques to reduce
this problem, it is advisable to perfonn ISH on cells as soon as possible after they are

processed.

V.5. In situ bybridisation

The variation of in situ hybridisation protocols found in this study, and from
laboratory to laboratory, reflects the common difficulty in establishing the technique.
Even though the use of ISH is becoming more widespread in molecular biology, as
Stahl & Baskin (1993) point out ISH is essentially a histochemical method and, as
such, not only requires 'getting it to work' but also verifYing that 'it is working
properly'. Concerns of signal specificity, sensitivity, resolution and controls must be
addressed in order to usc ISH as a diagnostic test. Although some degree of success

was accomplished with re,r.;pect to the use of in situ hybridisation in the present study,
further detailed investigation is needed in the optimisation of the procedure. Specific
hybridisation signal detection tiiid t1c reduction of background signal must be
improved to make ISH a viable diagnostic test in the detection of DGS and related
microdeletions. However some evidence from this study suggests that ISH will
provide a valuable test for DGS. For example, figure IV.ll shows a mother with an
apparent 22qll deletion, detected by ISH; susequently her son was also shown to
have this deletion by HRS karyotype analysis (see figures IV.4-IV.7). An infant who
was shown to have a microdeletion of chromosome 22qll with ISH, using a DIG-
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labelled Cl79, has since died as the result of complications due to VSD cardiac

disease, post mortem examination revealed classic symptoms of DGS.

The use of a digoxigenin labelled probe visualised by anti-digoxigenin HRP and

DAB allowed the use of a light microscope rather than a fluorescent instrument.
This form of detection is preferable to fluorescent microscopy because the signal on
slides is pennanent.

Thus, they can be hybridised immediately after the cell

suspension is processed (which reduces interference from cytoplasm and
concomitantly increases signal intensity) and then stored for analysis at a later time.
One of the major disadvantages with this detection method is, however, that after
hybridisation when chromosomes are counterstained and mounted they cannot be
banded to identifY individual chromosomes. This can be overcome by the use of
anoL1.er probe which is specific to the chromosome of interest, e.g., towards the end
of the study a stab culture containing a probe which is specific for the telomeric
region of chromosome 22 was made available by the Newcastle upon Tyne group.
The probe was prepared from a kanamycin-resistant bacterium as previously
described and run on a mini-gel to assess the purity of the isolated DNA (see
Appendix I. figure VII .I). The probe has been stored at this stage and with further
purification and labelling will be available for future use as

another control.

Conversely, FISH has the advantage over other forms of non-isotopic in situ
hybridisation because it allows the Q-banding of hybridised chromosomes which

enables their rapid identification. Unfortunately, it is not however as simple to detect
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a FISH signal using a fluorescent microscope as it is to detect DAB signal on the
light microscope. For this reason, many investigators use confocal laser scanning

microscopy or cooled CCD cameras in order to detect signal from FISH and identifY
individual chromosomes (Stahl and Baskin, 1993).

V.6. Conclusions and future investigations

The purpose of the present study was to explore the various possible techniques for
the detection of hybridisation signal in non-isotopic in situ hybridisation, and to
compare them with cytogenetic techniques using a probe specific for chromosome
22q 11. Variability exists at every stage of the ISH reaction. Investigators must
deduce what type of isolation, l8belling, hybridisation and detection protocols are
appropriate for use with each specific probe. Not only must hybridisation signal be
maximised and background signal minimised, but chromosome morphology has to
be retained in order to identify which chromosomes actually have signal. This fr. ... tor
conveys both advantages and disadvantages. For example, when the stringency of
the washing solutions is increased by raising the fonnamide concentration, or by
increasing the temperature and decreasing the concentration of

sse,

non~specific

signal is reduced. However, changes of this nature in the protocol also have an

adverse effect on chromosome morphology. Although all ISH protocols are based
on the same principles, it is only by investigative trial and error that optimal
conditions for ISH with specific probes and reagents can be achieved. During the
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course of this study several protocols were tried with two probes in order to achieve

hybridisation signal on metaphase chromosome spreads.

It is envisaged that the information obtained in this study regarding the degree of
success achieved with each of the experimental protocols tested will help future

researchers who wish to use the probe. Over 100 patients were examined and bled as
part of this study at Princess Margaret Hospital for Children (WA). All of these
samples have been cultured and processed at the Cytogenetics Department of SHLS,
and are now ready for ISH studies.

An amniotic fluid sample and fetal tissue

samples were also processed, then cryogenically treated and stored at -70°C for

future investigation into the use of ISH for DGS. Results of these continuing studies
will further advance our understanding of disorders such as DGS which display

marked genetic heterogeneity, and as a result the counselling of affected individuals

and their families should improve.
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Appendix I
Figure VII.1: Mini-gel resulting from maxi-preparation of cosmid probe specific for
telomeric region of chromosome 22:
Only lanes whose wells were loaded are numbered. Lane 1 is at the left hand side of
the gel. Lanes 1-6 all contain 1J.Ll of cosmid probe and 1J.Ll of loading buffer, lane 7
contains 1OJ.Ll of cosmid probe and 2J.Ll of loading buffer and lane 8 was loaded with
A.-Pstl. With further purification and labelling this probe could be used to identify
chromosome 22.
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Appendix ll

The clinical research proposal for this study by Dr. Sharon Worthington, Princess
Margaret Hospital for Children, WA.
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TITLE:

THE CLIN!CAL; AND MOLECULAR
CONGENTTAL HEART DISEASE

DNA

STUDY

OF

FAMILIAL

AIMS:
M3inaim:

To investigate chromosome 22q II in patients and their families with CATCH

22 disorders.

'

Specific aims:

I.

To explore in detail the clinical spectrum of the individual syndromes
embraced by the acronym CATCH 22.

2.

To explore the inheritance pattern ofthese disorders.

3.

To determine the prevalence of these conditions in the West Australian
population.

4.

To provide more accurate data about the natural history of these
disorders upon which to base genetic couselling for a specific group of
heart defects.

BACKGROUND
The incidence of congenital heart disease(CHD) is approximately one percent of live births(!).

Recent advances in cardiac surgery have resulted in long term survival of patients with complex
CHD into adulthood. As a consequence there has been increased interest into the genetics of
CHD. For the patients, their parents and extended families the recurrence risks and the
possibility of prenatal diagnosis are important issues.

Recurrence risks for CHD depend upon the mode of inheritance. Chromosomal abnormalities
occur in twelve percent of CHD whereas three percent of CIID is due to classical Mendelian
gene effects with recurrence risks of up to 50 percent(!). In most types of CHD however, the

inheritance pattern is complex and is assumed to be of the multifactorial type with recurrence
risks of3-5 percent depending on the type of lesion(!). This model assumes that the cause of

the defect is due to the effects of several genes which are modulated by environmental factors,
but it does not adequately explain the higher risks for some farru1ies ofCHD or the increased risk
for specific anatomic defects such as obstructive lesions ofthe left side of the heart(2).

CIID may be associated with exiracardiac manifestations as part of an identifiable malformation
syndrome. In 1981 an association was noted between abnormalities of chromosome 22 and the
DiGeorge Sequence(DGS)(3), Subsequent investigations have shown deletions of22qll at the
DiGeorge Critical region(DGCR) in 83 percent of cases ofDGS(4). It has been postulated that

these genes may play a role in neural crest cell migration which may be critical to the
development of the normal conotruncus(S) with deletions resulting in CHD. This theory is

supported by evidence of teratogenic· actiori of tretinoin which can produce very similar fetal
defects(6).

Submicroscopic deletions of chromosome 22q 11 have been associated with other syndromes
such as Vela-Cardia-Facial Syndrome(VCFS) in 65-70 percent of cases(4), Conotruncal
Anomaly Face Syndrome(CTFA) in 10-30 percent of cases(?), and the CHARGE association.
These syndromes share common features(see table 1) and the acronym CATCH 22 (Cardiac,
Abnormal facies, Thymic hypoplasia, Cleft palate and Hypocalcemia) has been coined to

encompass this group of disorders associated with deletions of chromosome 22(8).
Nonsyndromal CHD has also been associated with deletions of chromosome 22q 11. Patients
with conotrucal defects, a cardiac defect which is overrepresented in the CATCH 22 disorders,
have deletions of chromosome 22q 11 in 29 percent of cases(9). Deletions of chromosome
22qll also occur in familial CHD(IO).

Recurrence risks for these disorders vary from one to fifty percent and is dependent upon the
inherited pattern, gene deletions or other chromosomal abnormality and other causes such as
drugs. Counselling for patients with DGS and VCFS where a chromosome 22q II deletion is

present in both the child and one of the parents is for an autosomal dominant inheritance with a
recurrence risk of 50 percent. The risk is negligible if the parents are definitely unaffected.
Genetic counselling of these disorders is limited by difficulties in diagnosis and lack of
knowledge of the mode of inheritance of these disorders. Identification of patients with the
CHARGE association and VCFS can be difficult because of the variability of these conditions
and they are thus commonly underdiagnosed(ll). Cases reported in the literature thus far have

come from only a few centres and have been identified through craniofacial centres or genetic
units.

In Western Australia there is a centralised service for the treatment of cardiac defects which
would be ideal to study the population for the prevalence and natural course of these disorders.
In the proposed study we intend to identifY families with the CATCH 22 disorders in WA from
the Birth Defects Registry and from the cardiology department and investigate chromosome
22qll.

2

MECHANISMS FOR PHENOT,YPE-GENOTYPE CORRELATIONS
The mechanism of inheritance of these disorders has not been established. There is a wide

spectrum of clinical manifestations with the potential for more severe birth defects occurring
wi(h future generations(9). Numerous mechanisms have been postulated to explain these
manifestations. Schmickel suggests tha.t DGS is a contiguous gene syndrome with hemizygosity
for several genes resulting from the loss of multiple single genes in a small deletion(13).
Contiguous genes are genes which are physically adjacent on a chromosome but are otherwise
unrelate'd. A broad spectrum of clinical abnonnalities occur due to the wide range of molecular
defects caused by the loss of these unrelated genes. Tills concept can explain interl'am.ilial
differences but does not adequately explain differences in expression of these disorders between
family members.

The intrafarnilial differences could be due to parental mosaicism"with no mosaicism in the more
severely affected child or an expanding mutation increasing in severity with each generation(4).
The apparent increase in severity with a subsequent generation may be a result of selection bias
of previous studies as they have not included children with the less severe manifestations of
these disorders. Epigenic phenomena, that is genes at separate loci or envi~onmental factors
could modifY the effects of those genes deleted resulting in intrafamilial variability( I OJ. The
effects ofmatemal transmission and parental origin of deletions are other mechanisms that have
not been adequately explored in these disorders.

The proposed population based project will explore the clinical spectrum and the genetics of
these disorders to establish more accurate genetic counselling and thus more meaningful
prenatal diagnosis.

LABORATORY METHODS
Deletions of chromosome 22qll have been defined utilizing a number of molecular genetic
techniques. Cytogenetic studies reveal chromosome abnormalities in only 15~2(1% of DGS
cases. Molecular investigation with gene dosage analysis is a much more sensitiv~ technique but
is very time consuming(14). Gene dose analysis involves using densitometry to quantatively
analyse Southern blots to detennine the number of copies of a locus(identified by probes specific
for that locus) that are present. Homozygosity occurs if there are two copies of the locus(these
are unaffected individuals) and hemizygosity if only one copy is present(affected individuals).
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Fluorescence in situ hybridization(FISH) has been shown to be a more efficieht and direct
method for detection of22qll ~eletions in subjects with CATCH 22 disorders(l4,15). In situ
hybridization is a technique used to identifY the chromosomal location of genes directly by
hybridization of genomic or complementary DNA in situ to the DNA of a cytological

preparation. This technique is currently being used to more accurately define the limits of the
DCGR. For diagnostic purposes a probe specific for the areas of interest is labelled with an
antibody and hybridised to its matchi~g DNA sequence on a cytological preparation from the

patient. The preparation is counterstained with a dye which fluoresces and this is viewed using a
fluorescence microscope. If a hybridisation signal is seen on only one of the chromosomes 22
this is consist'ent with gene deletions in the 'region recognised by the probe.

PROTOCOL
I, ST!Y.)Y POPULATION
S~bjects

with VCFS, DGS, CTFA, the CHARGE association and those with cardiac defects
associated with facial dysmorphism or palatal abnormalities will be identified from the Birth

Defects Registry of WA. Further information concerning these patients will be obtained from
medical records at Princess Margaret Hospitai(PMH), the Cardiology and Genetic Departments
atPMH.

Subjects with familial CHD or specific cardiac defects of obstruct!ve lesions of the left and right
side of the heart will be identified from the Cardiology Department Records.

2. DATA SHEE.T
A request to access information from the Birth Defects Registry has been submitted. The
project has been approved by the cardiologists at PMH. It is assumed that most of the patients
will have consulted the Geneticists or Cardiologists at PMH. Where this is not the case, their
consultant will be contacted by letter(see letter I) and a request for the patient's inclusion in the
trial will be made.

3. RECRUITMENT TO STUDY
Parents will be sent information as an introduction to the trial by mail(see letter 2). They will
then be approached by telephone and arrangements for an interview will be made. Initial work

will involve examination of the proband for confirmation of diagnosis of the aforementioned
syndromes. An information sheet(see attached) regarding the study will be given to the parents
at the interview and consent(see attached) for inclusion in the study obtained. Diagnosis of the
individual syndromes will be made according to accepted criteria(see table I).
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4, FlJRTHER CLINICAL DATA
For the families who fulfill the inclusion criteria, an assessment of their pedigrees will occur
during the interview. Further examination of other affected family members maybe requested.
Infonnation concerning possible intrauterine infections, alcohol intake, and medications that may
have been taken during the pregnancy Will also be obtained.
5, TESTING FOR 22qll MICRODELETIONS

Blood samples will be obtained from the subjects and members of the families for DNA analysis.
A FISH assay will be used to detect deletions of chromosome 22qll. Laboratory work will be
done at the Cytogenetic State Health Laboratory .
6. CONFIDENTIALITY AND SECURITY
Information regarding the patients involved will be stored in the genetics Department at PMH in
a locked room as is routine for all patients seen at PMH genetics clinics.
7. LIMITATIONS OF STUDY
There is a wide spectrum of clinical manifestations of these CATCH 22 disorders and it will not
be possible to include the milder forms, for example isolated learning disorders. Parents or
siblings of the proband however, may have milder forms of these disorders and will give an
indication of their spectrum.
In this study only the immediate family will be tested for deletions of chromosome 22qll.
Extended family members who wish further information or investigation will be referred to the
Genetics outpatient clinic.

In summary, this study will explore the clinical and genetic aspects of the CATCH 22 disorders
to gain infonnation on their prevalence in the community, the relationship between the clinical
course of the disorder and the gene de!etion/s on chromosome 22 and the inheritance pattern of
these disorders. This information will allow more accurate genetic counselling for families in the
future.
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TABLE 1 : CLINICAL FEATURES OF SYNDROMES ASSOCIATED WITH DELETIONS OF CHROMOSOME 22q11

CAIU>U\C DEI1ECf

P<iS{8,1l)

PAI..ATAI.

.

I~NI>OCIUNI~

IMl\l~NE

I'S\'CIIIATUIC

dcvdopm.:nt

thymic aplasia or

hypoth}TOidislll

nonn<~lto

hYf.opla.sia.

vcloph:lryngcnl

...:~-.:r.;:ly

inw 1' o.:lls

incompcte.Jcc

delayed

c;,r:o;Jow s-.'1, o;:iro;u]ar

den

I'NVSD

n:urow p:!.lpcbrnl Ii:osur.:s

high ~rchcd

TOF
DORV
TA

prominent n:IS.ll mol
sm:r.llmouth

STA1'URI•:

hypocah:cmia

IM

OTJIEit

DMFNH.SS

,_,

coloboJM

rc:nal ab!XIml.

short philtrom

VSD
TOF
DORV

VCFS(ll,16)

FACIALADNOHMAI..JT\'

PNVSD

IM

=: promin~-nt, circular

clcn

bro3d n=l root, long n010c

vdoph.al)'llgcal

myopaU1ic facies
Pierre Robin Scqucnc:c

in~vmpctcncc

ADDH

high ar<:l1cd

depression

flattened

short

hypoclllccmi:~

)QIJ\ing

hypothyroidiSJII

difficulti.:s

mal~

.

:o~bnorm:t!Tccll

limction can occur

hypotonia
long fingCI'$

psycllwo:s

small mandible
<::!Llr.lds, strD bi!;lliUS

narrow palpcbrnl Ii~urcs

TOf
PA

CTAF(7)

...

.

low set ears

cleft

ln~lform~d :;~uricl~s

hisharch~d

~mJII

11.'1.~3[ ~pcccl1

mouth

.

.

mild mental

.

o;onduetivc

.

retardation

short palpcbrnl fissures

.

ptosis, strabismus

hypcrtelorisn1
low n=l bridge

CUAROE{I7,18)

PDA
VSD
TO It
DORV

'

.

.

vdophal)11gcal

mi®ph.lUus
Q)ptorc:hidWn
CNS n1alfomution

incompctciiCC

DOS

choana! atresia

cleft

poorly fosmcdhclixor~
colobomn
hypcrtelooism

high arched

~hort

mental

present

~tar&lion

small mamlible

DOS ..

DIG~ORGE SEQUENCE

VCFS • VELC-CARDIO-FACitU.SYNDROME
CTAF- CONOTRUNCAL ANOMAL'{ FACE SYNDROME

DORY= DOODLE OUTLET JUG!ll. VENTRICI..S

IM -IN'runRUI'TEO AORTIC t\RCII
I'A .. J'ULMOllARY ATRESIA
VSD,. VENTRICULAR SEPTAL DEFECT

TA .. TRUNCUS ARTERIOSUS

TOF=TETRALOGY OFFALLOT

ADDH .. ATIENT!ON DEFICIT DISORDER AND liYPERACTJVJlY

PDA =PATENT DUCTIIS ARTERJSOUS

HEART DEFECTS IN FAMILI~S AND THEIR GENE ABNORMALITIES

INFORMATION SHEET FOR PARENTS

Many children are born with heart defects which vary in severity. Some complex defects
cause death, others may require major heart surgery, and some are minor requiring no

treatment. Causes of heart defects include· infections and drugs taken during the pregnancy
and heredity, but more frequently the cause is unknown.

At Princess Margaret Hospital the Cardiology and Genetic Departments are looking more
closely St heart defects that may have a genetic cause. Specific heart defects that may be
associated with other birth defects and may run in the family 3.re known to occur when

genes are missing on human chromosome 22.

We intend to look at all children in Western Australia with these heart defects to see if there
are other minor birth defects that may not be obvious and assess their families for heart and
birth defects. The study will determine how common these conditions are in W.A. and give
us a better understanding of how they may possibly be passed on to other family members.
The information obtained could be of great benefit to you and your family.
If you agree to participate in the study, it will involve your family and children being seen in
a genetic clinic at the hospital, asse',;sing the family tree and an examination to look for
other minor birth defects. It will also require the taking of a blood sample from your child
and possibly other family members to look at chromosome 22 for missing genes.
All information about an individual family and thei, test results will be confidential. Refusal
to participate in the study will in no way jeopardise your child's medical management.
Any queries should be directed to Dr S Worthington at the genetics department at PMH,
telephone number 340 8354.

SHARRON WORTHINGTON
Paediatric Registrar
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RESEARCH & ETHICS SUU-COMilliTI'EE COVER SHEET
TITLE OF PROJECT:
HEART DEFECTS IN FAMILIES AND THEIR GENE ABNORMALITIES
LAY DESCRIPTION:

'.

Approximately one out of every I 00 children is born with an abnormality of the heart. • There are
many different types of heart defects with complex heart defects resulting in death of a child at a
young age and other heart problems that maybe sufficiently minor not to interfere with the child's
lifestyle. Many of the major heart defects are now correctable by heart surgery . Therefore there
are now many adults who have had heart defects and who are contemplating families. The risks to
their children and relatives of inheriting heait defects are important issues.
Some heart defects recur in families and are sometimes associated with an abnormality of
chromosome 22. Specifically, there are genes that are missing from part of this chromosome.
These heart defects which may be quite complex and in some cases result in death of the child can
also be associated with other birth defects as part of a syndrome.
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In this study, children with heart defects and some syndrom~s will be identified from the Birth
Defects Registry and the Cardiology Department at Princess Margaret Hospital. The children and
their families will be notified about the study by mail. They will then be approached by telephone
to arrange an interview, during which further information about heart defects and other disorders
that may be prese:1t in the family will be sought. Family members may need to be examined to see
if they have subtle features of these disorders. An information sheet will be given to the parents at
the interview and if they agree to their child entering the study a they will be asked to sign a
Standard consent form. A blood sample will be taken from the children and possibliy other
members of the family to look for missing ger.es on chromosome 22.
The study will identity a group of children with specific heart defects which are associated with
missing genes on chromosome 22. Children and parents with this chromosome abnormality have a
high risk of giving birth to children with heart defects which may be even more severe than their
own. The information gained form the study will enable doctors to give more accurate advice to
people about these disorders when they are contemplating families. Questions such as how
severely the child may be affected, the type of heart lesions that may occur, other physical
abnormalities the child could have, how disabled the child may be, and the likelihood of having a
'normal versus an affected child may be ansv,•ered. It may be possible to prevent these defects by
looking for this gene abnormality in the baby during pregnancy.

"PJsksn to the subjects and their families are the potential for discovery of physical abnormalities or
diagnosis of a syndrome not previously recognised. Appropriate genetic counselling will be
arranged if this occurs.
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